[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 230
1. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D: Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther; 2010 Jan;18(1):161-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.
  • As expected, the shRNAs silenced hepatic p53 and accelerated liver tumorigenesis when MYC was concurrently expressed.
  • In MYC-expressing transgenic mice, the marginal shRNA-induced liver injury sufficed to further stimulate hepatocellular division that was in turn associated with markedly increased expression of the mitotic cyclin B1.
  • Hence, even at low doses, shRNAs can cause low-level hepatoxicity that can facilitate the ability of the MYC oncogene to induce liver tumorigenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / chemically induced. Genes, myc / physiology. Liver Neoplasms, Experimental / chemically induced. RNA, Small Interfering / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Gene Ther. 2001 Aug;8(16):1248-54 [11509958.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6487-93 [11522645.001]
  • [Cites] Adv Cancer Res. 2002;84:81-154 [11885563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Semin Liver Dis. 2002;22(2):137-44 [12016545.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):290-4 [12529648.001]
  • [Cites] Curr Gene Ther. 2003 Aug;3(4):281-304 [12871018.001]
  • [Cites] Front Biosci. 1998 Feb 15;3:d250-68 [9468463.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Pharmacol Ther. 1989;43(1):139-54 [2675128.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1145-56 [2598264.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3400-7 [1692259.001]
  • [Cites] Cell. 1993 Nov 5;75(3):451-62 [8106172.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1237-45 [7977654.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1316-25 [7557887.001]
  • [Cites] J Virol. 1996 Jul;70(7):4646-54 [8676491.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15639-45 [9624157.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):41-9 [9934848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2934-41 [10378690.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Semin Liver Dis. 1999;19(3):243-52 [10518304.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] J Virol. 2005 Jan;79(1):214-24 [15596817.001]
  • [Cites] Methods Enzymol. 2005;392:381-405 [15644194.001]
  • [Cites] Toxicol Pathol. 2005;33(1):181-4 [15805070.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):942-4 [15611633.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):563-75 [16453009.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Methods. 2006 Sep;3(9):689-95 [16929313.001]
  • [Cites] Genome Biol. 2006;7(8):231 [16942630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14917-22 [17848523.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] J Virol. 2008 Jun;82(12):5887-911 [18400866.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19184-91 [18456653.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22186-92 [18524776.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1630-6 [18665161.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Oct;9(10):810-5 [18698328.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1005-17 [19524505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:42-65 [10836127.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):168-73 [10942533.001]
  • [Cites] J Virol. 2001 Aug;75(15):6969-76 [11435577.001]
  • (PMID = 19844192.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA03423; United States / NCI NIH HHS / CA / R01-CA89305; United States / NIDDK NIH HHS / DK / DK078424; United States / NCI NIH HHS / CA / F32-CA132312; United States / NCI NIH HHS / CA / R01 CA089305; United States / NCI NIH HHS / CA / F32 CA132312; United States / NIDDK NIH HHS / DK / R01 DK078424; United States / NCI NIH HHS / CA / P50-CA114747; United States / NCI NIH HHS / CA / R01 CA105102; United States / NCI NIH HHS / CA / R01-CA105102; United States / NCI NIH HHS / CA / P50 CA114747
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2839214
  •  go-up   go-down


2. Soon JL, Jeyaraj PR, Agasthian T: Thoracic complications of radiofrequency ablation of recurrent hepatoma. Ann Acad Med Singapore; 2008 Jan;37(1):75-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic complications of radiofrequency ablation of recurrent hepatoma.
  • INTRODUCTION: Radiofrequency ablation (RFA) for unresectable primary or secondary hepatic malignancies have gained widespread availability and acceptance over the past 5 years.
  • CLINICAL PICTURE: We report a patient with symptomatic right pleural effusion due to a diaphragmatic fistula and another with biliptysis post-RFA, for recurrent hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Diaphragm / physiopathology. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Fistula / etiology. Humans. Male. Pleural Effusion / etiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265903.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


3. Yang PW, Wang WY, Yang CH, Chou CC, Yen DH, Chou J: Treatment of massive retroperitoneal hemorrhage from adrenal metastasis of hepatoma. J Chin Med Assoc; 2007 Mar;70(3):126-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of massive retroperitoneal hemorrhage from adrenal metastasis of hepatoma.
  • Herein, we report a case of hepatocellular carcinoma (HCC), where left hepatic lobectomy and right adrenalectomy for metastatic HCC were performed in April and August 2002, respectively.
  • Metastatic adrenal tumor bleeding should be suspected in hepatoma patients who suffer abrupt flank pain and shock.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Hepatocellular / pathology. Hemorrhage / therapy. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Retroperitoneal Space. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17389158.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Aydinli M, Harmanci O, Ersoy O, Iskit AT, Ozcebe O, Abbasoglu O, Bayraktar Y: Two unusual cases with Wilson's disease: hepatoma and fulminant hepatitis treated with plasma exchange. J Natl Med Assoc; 2006 Dec;98(12):1989-91
MedlinePlus Health Information. consumer health - Wilson Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two unusual cases with Wilson's disease: hepatoma and fulminant hepatitis treated with plasma exchange.
  • Alpha-fetoprotein level was found elevated and computed tomography showed a 3.5-cm liver mass.
  • Hepatocellular carcinoma was diagnosed.
  • Radiofrequency ablation and liver transplantation were performed successfully.
  • To conclude, although hepatoma is rarely seen in Wilson's disease, patients should be examined regularly to diagnose it in a treatable stage.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatolenticular Degeneration / complications. Liver Failure, Acute / etiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Female. Humans. Liver Transplantation. Male. Plasma Exchange

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1995 Oct;23(4):373-81 [8655953.001]
  • [Cites] Transfusion. 1998 Apr;38(4):327-31 [9595013.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Ann Intern Med. 1999 Dec 7;131(11):866 [10610638.001]
  • [Cites] Q J Med. 1989 Mar;70(263):253-63 [2602537.001]
  • [Cites] Intern Med. 2003 Oct;42(10):967-70 [14606709.001]
  • [Cites] Gastroenterology. 1983 Jan;84(1):161-7 [6847842.001]
  • [Cites] Gut. 1983 Aug;24(8):767-71 [6307837.001]
  • [Cites] QJM. 2003 Sep;96(9):657-62 [12925721.001]
  • (PMID = 17225847.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569669
  •  go-up   go-down


5. Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM: Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Dig Dis Sci; 2010 Nov;55(11):3052-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature.
  • BACKGROUND: Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular bile ducts and cholestasis, rarely associated with hepatocellular carcinoma.
  • As such, we herein review the modern management of a large hepatocellular carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with hepatocellular carcinoma.
  • CASE PRESENTATION: A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 12 × 8 cm hepatocellular carcinoma replacing her right liver.
  • Biopsy of the contralateral liver demonstrated findings consistent with Alagille syndrome, but no underlying cirrhosis.
  • CT volumetrics demonstrated a future liver remnant of 40%.
  • [MeSH-major] Alagille Syndrome / epidemiology. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / epidemiology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Comorbidity. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


6. El-Tahir HM, Dietz F, Dringen R, Schwabe K, Strenge K, Kelm S, Abouzied MM, Gieselmann V, Franken S: Expression of hepatoma-derived growth factor family members in the adult central nervous system. BMC Neurosci; 2006;7:6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatoma-derived growth factor family members in the adult central nervous system.
  • BACKGROUND: Hepatoma-derived growth factor (HDGF) belongs to a polypeptide family containing five additional members called HDGF related proteins 1-4 (HRP-1 to -4) and Lens epithelial derived growth factor.
  • Here we investigated the expression of HDGF, HRP-2 and HRP-3 in the central nervous system of adult rats on the cellular level by immunohistochemistry.
  • In addition we performed Western blot analysis of various brain regions as well as neuronal and glial cell cultures.
  • In contrast, strong expression of HRP-3 in the adult nervous system is restricted to neurons, except for very weak expression in oligodendrocytes in the brain stem.
  • CONCLUSION: The coexpression of HDGF and HRP-2 in glia and neurons as well as the coexpression of all three proteins in many neurons suggests different functions of members of the HDGF protein family in cells of the central nervous system that might include proliferation as well as cell survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 9;266(1):81-7 [10581169.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55570-7 [15475359.001]
  • [Cites] J Clin Invest. 2000 Mar;105(5):567-75 [10712428.001]
  • [Cites] Dev Neurosci. 2000 Sep-Dec;22(5-6):384-92 [11111154.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37564-8 [11481329.001]
  • [Cites] Dev Dyn. 2001 Nov;222(3):450-8 [11747079.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10315-22 [11751870.001]
  • [Cites] J Neurochem. 2002 Aug;82(3):635-44 [12153487.001]
  • [Cites] Biochem J. 2002 Sep 1;366(Pt 2):491-500 [12006088.001]
  • [Cites] Hepatology. 2002 Dec;36(6):1519-27 [12447878.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):372-81 [12407101.001]
  • [Cites] J Gastroenterol. 2002 Nov;37 Suppl 14:158-61 [12572885.001]
  • [Cites] J Neurosci Res. 2003 Aug 1;73(3):400-9 [12868073.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33528-39 [12796494.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1444-56 [14508832.001]
  • [Cites] Brain Res. 2003 Nov 21;991(1-2):163-70 [14575888.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6716-25 [14583466.001]
  • [Cites] Cancer Sci. 2003 Dec;94(12):1034-41 [14662017.001]
  • [Cites] Biochem J. 2004 Feb 15;378(Pt 1):169-76 [14572309.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 19;315(4):950-8 [14985104.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1194-201 [14751852.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27320-6 [15140875.001]
  • [Cites] J Virol. 2004 Sep;78(17):9524-37 [15308744.001]
  • [Cites] J Mol Biol. 2004 Nov 5;343(5):1365-77 [15491618.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Methods Enzymol. 1985;109:341-5 [2985921.001]
  • [Cites] Brain Res. 1985 Oct 7;344(2):322-8 [2994839.001]
  • [Cites] J Neurosci. 1988 Dec;8(12):4780-9 [3199205.001]
  • [Cites] Clin Chim Acta. 1989 Aug 31;183(3):273-84 [2553304.001]
  • [Cites] J Neurochem. 1990 May;54(5):1474-83 [1691273.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):25143-9 [7929202.001]
  • [Cites] Development. 1996 Feb;122(2):555-66 [8625807.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):26-32 [9299445.001]
  • [Cites] Mol Cell Proteomics. 2005 Jan;4(1):44-55 [15567892.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):10945-54 [15655245.001]
  • [Cites] Neuron. 2005 Jul 21;47(2):201-13 [16039563.001]
  • [Cites] J Neurosci Res. 1997 Oct 15;50(2):139-45 [9373024.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1208-19 [9739055.001]
  • [Cites] J Neurochem. 1999 Jun;72(6):2523-30 [10349863.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 27;262(2):433-7 [10462493.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48883-92 [15371438.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1301-5 [15543146.001]
  • [Cites] J Pediatr Surg. 2000 Jan;35(1):113-8; discussion 119 [10646787.001]
  • (PMID = 16430771.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Nerve Tissue Proteins; 0 / hepatoma-derived growth factor; 0 / hepatoma-derived growth factor-related protein-3, rat
  • [Other-IDs] NLM/ PMC1363353
  •  go-up   go-down


7. Lin YS, Jung SM, Tsai FC, Yeh CN, Shiu TF, Wu HH, Lin PJ, Chu PH: Hepatoma with cardiac metastasis: an advanced cancer requiring advanced treatment. World J Gastroenterol; 2007 Jul 7;13(25):3513-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma with cardiac metastasis: an advanced cancer requiring advanced treatment.
  • AIM: To investigate the clinical and pathologic findings, and to discuss the pathophysiology of hepatocellular carcinoma with cardiac metastasis.
  • METHODS: Eight hepatoma patients with cardiac metastasis, who were treated by surgical excision from 1993 to 2006, were retrospectively studied.
  • CONCLUSION: Hepatoma metastasis to the heart was detected in all eight patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Heart Neoplasms / secondary. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1259-62 [15362727.001]
  • [Cites] Int J Clin Pract. 2004 Jun;58(6):564-7 [15311555.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):289-98 [2416627.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):52-5 [15568157.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):212-6 [15783033.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):822-7 [15696123.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):425-9 [16012295.001]
  • [Cites] World J Surg. 2005 Jun;29(6):715-8 [16078127.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(2):151-69 [10741273.001]
  • [Cites] Chang Gung Med J. 2001 Feb;24(2):97-102 [11360408.001]
  • [Cites] J Am Soc Echocardiogr. 2004 Feb;17(2):192-4 [14752497.001]
  • [Cites] Int J Clin Pract. 2004 Mar;58(3):306-9 [15117101.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):497-513 [15205947.001]
  • [Cites] Acta Pathol Jpn. 1984 Jul;34(4):839-45 [6091401.001]
  • (PMID = 17659700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC4146789
  •  go-up   go-down


8. Enomoto H, Nakamura H, Komatsu-Kanatani N, Liu Y, Yoshida K, Okuda Y, Yamamoto T, Liu W, Nishiguchi S: Partial blockage of hepatocyte maturation in hepatoma-derived growth factor transgenic mice. World J Hepatol; 2009 Oct 31;1(1):98-102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial blockage of hepatocyte maturation in hepatoma-derived growth factor transgenic mice.
  • AIM: To investigate the role of hepatoma-derived growth factor (HDGF) in liver development, especially in the hepatocyte differentiation.
  • RESULTS: The HDGF transgenic mice developed normally and showed no apparent abnormality in the liver.
  • However, the gene expression patterns of the liver in adult transgenic mice were similar to those of the neonatal liver in control mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160971.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999260
  • [Keywords] NOTNLM ; Hepatocyte / Hepatoma-derived growth factor / Maturation / Transgenic mice
  •  go-up   go-down


9. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, Ochiai T, Saisho H: Identification and investigation of methylated genes in hepatoma. Eur J Cancer; 2005 May;41(8):1185-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and investigation of methylated genes in hepatoma.
  • Previous microarray analysis demonstrated that 14 genes, including hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI2/PB) gene, showed particularly high inductions after 5-aza-2'deoxycytidine (5Aza-dC) treatment in multiple hepatoma cell lines.
  • Aberrant methylation in primary hepatoma tissues was also examined using methylation-specific polymerase chain reaction (MSP).
  • Genes for E-cadherin, collagen type I alpha 2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), connective tissue growth factor (CTGF) and fibronectin 1 exhibited aberrant methylation in several hepatoma cell lines.
  • In further studies of 24 primary hepatoma tissues, methylation signals for COL1A2, IGFBP2, CTGF and fibronectin 1 were detected in 13, 18, 4 and 10 patients, respectively.
  • In conclusion, aberrant methylation of COL1A2, IGFBP2, CTGF and fibronectin 1 genes were detected in hepatoma cell lines.
  • The results of MSP in hepatoma tissues suggested that some of these genes might be involved in the development or progression of hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Complementary / genetics. Liver Neoplasms / genetics. Oncogenes / genetics
  • [MeSH-minor] Adult. Aged. Collagen Type I / genetics. Connective Tissue Growth Factor. CpG Islands / genetics. Female. Fibronectins / genetics. Histones / genetics. Humans. Immediate-Early Proteins / genetics. Insulin-Like Growth Factor Binding Protein 2 / genetics. Intercellular Signaling Peptides and Proteins / genetics. Male. Microarray Analysis / methods. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911243.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTGF protein, human; 0 / Collagen Type I; 0 / DNA, Complementary; 0 / Fibronectins; 0 / Histones; 0 / Immediate-Early Proteins; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / collagen type I, alpha 1 chain; 139568-91-5 / Connective Tissue Growth Factor
  •  go-up   go-down


11. Wilson FD, Fitzgerald SD, Kiupel M, Walker RL, Williams CB, Todd DJ: Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros). J Zoo Wildl Med; 2007 Jun;38(2):329-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros).
  • The liver was grossly enlarged and contained a smooth-surfaced nodular mass that occupied the majority of the right lobe of the liver.
  • The mass had a liver-like appearance exhibiting a tan-red coloration but having a soft consistency.
  • To our knowledge, this is the first report in the scientific literature of a naturally occurring case of hepatocellular carcinoma in a Nile lechwe or in any antelope species.
  • [MeSH-major] Antelopes. Carcinoma, Hepatocellular / veterinary. Liver Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679519.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Caja L, Ortiz C, Bertran E, Murillo MM, Miró-Obradors MJ, Palacios E, Fabregat I: Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal; 2007 Apr;19(4):683-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis.
  • Indeed, escaping from the TGF-beta suppressor actions might be a prerequisite for liver tumour progression.
  • In this work we show that TGF-beta plays a dual role in regulating apoptosis in FaO rat hepatoma cells, since, in addition to its pro-apoptotic effect, TGF-beta also activates survival signals, such as AKT, the epidermal growth factor receptor (EGFR) being required for its activation.
  • In contrast, TGF-beta does not activate AKT in adult hepatocytes, which correlates with lack of EGFR transactivation and no response to EGFR inhibitors.
  • Although TGF-beta induces TGF-alpha and HB-EGF in adult hepatocytes, these cells show very low expression of TACE/ADAM 17 (TNF-alpha converting enzyme), which is required for EGFR ligand proteolysis and activation.
  • Furthermore, adult hepatocytes do not undergo EMT processes in response to TGF-beta, which might be due, at least in part, to the fact that F-actin re-organization induced by TGF-beta in FaO cells require the EGFR pathway.
  • Finally, results indicate that EGFR transactivation does not block TGF-beta-induced cell cycle arrest in FaO cells, but must be interfering with the pro-apoptotic signalling.
  • In conclusion, TGF-beta is a suppressor factor for adult quiescent hepatocytes, but not for hepatoma cells, where it plays a dual role, both suppressing and promoting carcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Hepatocytes / drug effects. Hepatocytes / metabolism. Signal Transduction / drug effects. Transforming Growth Factor beta / pharmacology
  • [MeSH-minor] ADAM Proteins / genetics. ADAM Proteins / metabolism. Actins / metabolism. Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Enzyme Activation / drug effects. Epithelial Cells / cytology. Epithelial Cells / drug effects. Humans. Male. Mesoderm / cytology. Mesoderm / drug effects. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Rats, Wistar. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Transcriptional Activation / drug effects. src-Family Kinases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17055226.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  •  go-up   go-down


13. Zhang GQ, Wang HB, Gao P, Fang CH, Chen GH: [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients]. Zhonghua Wai Ke Za Zhi; 2009 Dec 15;47(24):1857-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients].
  • OBJECTIVE: To study the relationship between extrahepatic metastasis of primary hepatocellular carcinoma and circulative tumor cells in the blood of hepatoma patients.
  • METHODS: The immunomagnetic bead technique was employed to enrich and separate the hepatoma cells in the peripheral blood of preoperative and postoperative hepatoma patients.
  • The relationship between postoperative extrahepatic metastasis and hepatoma cells in peripheral blood cancer cells were analyzed.
  • The circulative tumor cells in the peripheral blood of hepatoma patients were enriched and separated by immunomagnetic bead technique.
  • They were identified as hepatoma cells by AFP immunohistochemistry.
  • Among 30 cases of hepatoma patients, the positive rate of hepatoma cells in the peripheral blood of preoperation and postoperation were 53.3% and 83.3% respectively.
  • CONCLUSIONS: Extrahepatic metastasis of primary hepatocellular carcinoma is obviously correlated to the positive tumor cells and the concentration in the peripheral blood of preoperative patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193401.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


14. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother; 2005 Mar-Apr;28(2):129-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.
  • A phase 1 study was conducted to assess the safety and immunologic response induced by direct injection of autologous immature dendritic cells (DCs) into tumor under radiotherapy in advanced hepatoma patients.
  • Patients with advanced/metastatic stage hepatoma not suitable for surgery or transarterial embolization were enrolled.
  • Six patients showed an increased NK cell cytotoxic activity after vaccination.
  • [MeSH-major] Cancer Vaccines. Carcinoma, Hepatocellular / radiotherapy. Combined Modality Therapy. Dendritic Cells / cytology. Immunotherapy / methods. Immunotherapy, Adoptive / methods. Liver Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Autoimmune Diseases. Cohort Studies. Cytokines / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Injections, Intralesional. Interferon-gamma / metabolism. K562 Cells. Killer Cells, Natural / cytology. Male. Middle Aged. Neoplasm Metastasis. Time Factors. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725956.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / alpha-Fetoproteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


15. Hu TH, Lin JW, Chen HH, Liu LF, Chuah SK, Tai MH: The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum; 2009 Feb;52(2):319-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors.
  • PURPOSE: This study investigated the expression and prognostic role of hepatoma-derived growth factor (HDGF) in colorectal stromal tumor.
  • Immunohistochemical studies were performed with antibodies of HDGF, proliferating cell nuclear antigen (PCNA) and Ki-67.
  • [MeSH-minor] Adult. Aged. Cell Nucleus / chemistry. Cytoplasm / chemistry. Disease-Free Survival. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279430.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / hepatoma-derived growth factor
  •  go-up   go-down


16. Wu W, Yao DF, Yuan YM, Fan JW, Lu XF, Li XH, Qiu LW, Zong L, Wu XH: Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int; 2006 Nov;5(4):538-44
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, its prognosis is poor, and early detection is of utmost importance.
  • To enhance the specificity and accuracy of AFP measurements for HCC, we analyzed AFP expression states in livers, detected the hepatoma-specific AFP (HS-AFP) fraction and AFP-mRNA from peripheral blood mononuclear cells, and explored their clinical implications for HCC diagnosis.
  • METHODS: AFP expression and hepatocyte distributions in liver specimens were investigated by an immunohistochemical assay.
  • In the HCC and liver cirrhosis groups, the incidence of HS-AFP was 91.7% and 18% (P<0.01), and of AFP-mRNA was 56.7% and 16% (P<0.01), respectively, and neither was found in controls.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver / metabolism. Liver Neoplasms / metabolism. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Hepatitis, Chronic / blood. Humans. Liver Cirrhosis / blood. Male. Middle Aged. RNA, Messenger / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085339.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  •  go-up   go-down


17. Martin RC 2nd, Loehle J, Scoggins CR, McMasters KM: Kentucky hepatoma: epidemiologic variant or same problem in a different region? Arch Surg; 2007 May;142(5):431-6; discussion 436-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kentucky hepatoma: epidemiologic variant or same problem in a different region?
  • BACKGROUND: Hepatitis and cirrhosis are common etiologic factors in hepatocellular carcinoma (HCC) in the United States.
  • HYPOTHESIS: Kentucky hepatoma, defined as a noncirrhotic, nonfibrotic, hepatitis-negative HCC, occurs in an older population with more favorable preoperative factors when compared with other patients with HCC.
  • These noncirrhotic, hepatitis-free patients were found to be significantly older (70 vs 55 years; P = .001), to be more often female (40.3% vs 24.4%; P = .01), to have a larger tumor size (6.5 vs 3.9 cm; P = .004), to have fewer liver lesions (1 vs 3; P = .22), and to more frequently undergo surgical therapy (75.6% vs 53.8%; P = .01) than the patients with cirrhosis or hepatitis (n = 41).
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / epidemiology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. SEER Program. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515484.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Zhang FJ, Li CX, Wu PH, Li K, Huang JH, Fan WJ, Zhang L, Gu YK, Lu MJ, Wu YX, Wang JJ: [Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma]. Zhonghua Yi Xue Za Zhi; 2007 Apr 10;87(14):956-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma].
  • OBJECTIVE: To investigate the clinical value of CT-guided radioactive seed (125)I implantation in treating recurrence and metastasis after liver transplantation in hepatoma.
  • METHODS: Eleven patients with recurrence and metastasis after liver transplantation for hepatoma, with 45 metastatic lesions, 2.5 cm in diameter on average totally 9 males and 2 females, aged 56 (35 approximately 68), underwent CT-guided radioactive seed 125I implantation for 33 man-times.
  • CONCLUSION: CT guided radioactive seed 125I implantation procedure has good clinical effects with minimal damage and few complications in treating recurrence and metastasis after liver transplantation in hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Iodine Radioisotopes / therapeutic use. Liver Neoplasms / radiotherapy. Neoplasm Metastasis / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy / adverse effects. Brachytherapy / methods. Female. Follow-Up Studies. Hemorrhage / etiology. Humans. Liver Transplantation. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650418.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


19. Zhang X, Dong N, Yin L, Cai N, Ma H, You J, Zhang H, Wang H, He R, Ye L: Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol; 2005 Nov;77(3):374-81
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues.
  • The hepatitis B virus X protein (HBx) plays an important role in the development of hepatocellular carcinoma (HCC).
  • The expression levels of HBV antigens (HBsAg, HBcAg, and HBxAg) and members of the IAP family (survivin, XIAP, cIAP-1, and cIAP-2) were detected immunohistochemically in tissues from 34 cases of HCC and 30 cases of liver cirrhosis.
  • The positive rates of HBxAg and survivin were high in HCC (76.5% and 88.2%), paratumor (85.3% and 91.2%), and liver cirrhosis (100% and 93.3%) tissues, with no significant differences between the survivin- and HBxAg-positive rates (each P > 0.05).
  • To examine the effect of HBx on survivin expression, plasmid pCMV-X (encoding the HBx gene) was transfected transiently with or without plasmid pcDNA3-sur (encoding the survivin gene) into H7402 hepatoma cells and L-O2 human normal liver cells.
  • To examine the effect of HBx on survivin in hepatoma cells without apoptosis, plasmid pCMV-X was transfected stably into human hepatoma H7402 cells and L-O2 cells.
  • Collectively, these data demonstrate that HBx upregulates survivin expression in hepatoma tissues, suggesting that HBx and survivin may both be involved in carcinogenesis of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Trans-Activators / metabolism. Up-Regulation
  • [MeSH-minor] Adult. Apoptosis / drug effects. Cell Line, Tumor. Flow Cytometry. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Liver Cirrhosis / pathology. Liver Cirrhosis / virology. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, inc.
  • (PMID = 16173017.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Trans-Activators; 0 / hepatitis B virus X protein
  •  go-up   go-down


20. Lin CS, Jen YM, Chiu SY, Hwang JM, Chao HL, Lin HY, Shum WY: Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol; 2006 Apr;36(4):212-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy.
  • BACKGROUND: Patients with hepatocellular carcinoma (HCC) often have unresectable tumors.
  • A more strict patient selection criterion may maximize the potential benefits of radiotherapy for hepatoma patients with PVTT.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplastic Cells, Circulating / pathology. Neoplastic Cells, Circulating / radiation effects. Portal Vein / pathology. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Prospective Studies. Survival Rate


21. Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Doki Y, Yoshida K, Aozasa K, Nakamura H, Monden M: Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res; 2006 Jan 1;12(1):117-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma.
  • PURPOSE: Hepatoma-derived growth factor (HDGF) is a unique nuclear/growth factor and might play an important role in the development and progression of carcinomas.
  • In the present study, association of HDGF expression with recurrence and prognosis of gastric carcinoma was examined.
  • PATIENTS AND METHODS: HDGF expression in 317 patients with gastric carcinoma (233 males and 84 females) with ages ranging from 26 to 81 years (median, 60 years) was analyzed by immunohistochemistry.
  • CONCLUSION: HDGF expression level was shown to be a prognostic factor for gastric carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / metabolism. Intercellular Signaling Peptides and Proteins / biosynthesis. Lymphatic Metastasis / pathology. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397032.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / hepatoma-derived growth factor
  •  go-up   go-down


22. Wang NY, Zhao W, Zhang D, Zhang YC, Duan MH: [Clinical application of avidin-biotin ELISA to detect serum hepatoma-specific gamma-glutamyltransferase in patients with primary hepatic cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):114-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of avidin-biotin ELISA to detect serum hepatoma-specific gamma-glutamyltransferase in patients with primary hepatic cancer].
  • OBJECTIVE: To detect serum hepatoma-specific datura stramonium lectin-tightly binding gamma-glutamyl transferase (DSA-GGT) in patients with primary hepatic cancer (PHC) by avidin-biotin ELISA method which was established in our laboratory, and carry on a study of its clinical application.
  • METHODS: To detect serum DSA-GGT in 45 healthy control subjects, 58 PHC patients and 203 non-PHC patients (including 36 patients with other tumors and 167 patients with benign liver diseases) with the method was established; meanwhile, AFP was detected by ELISA method.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. gamma-Glutamyltransferase / blood
  • [MeSH-minor] Adult. Avidin. Biotin. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BIOTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538886.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 1405-69-2 / Avidin; 6SO6U10H04 / Biotin; EC 2.3.2.2 / gamma-Glutamyltransferase
  •  go-up   go-down


23. Kar S, Wang M, Carr BI: alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis. Mol Cell Biochem; 2007 Oct;304(1-2):189-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis.
  • It has also been shown to have a mitogenic effect on primary endothelial cells, vascular smooth muscle cells, fibroblasts and some tumor cells, but is an inhibitor of rat hepatocyte DNA synthesis on fibronectin matrix in cell culture.
  • We now report that prothrombin is converted to alpha-thrombin by primary cultures of normal adult rat hepatocytes and alpha-thrombin is also a potent inhibitor of hepatocytes DNA synthesis.
  • In contrast, rat hepatoma cells cultured under similar conditions were resistant to alpha-thrombin mediated DNA synthesis inhibition.
  • However, no appreciable cell detachment was observed.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. DNA / metabolism. Hepatocytes / drug effects. Receptors, Thrombin / metabolism. Thrombin / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17516031.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82723
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Receptors, Thrombin; 9001-26-7 / Prothrombin; 9007-49-2 / DNA; EC 3.4.21.5 / Thrombin
  •  go-up   go-down


24. Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H: Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol; 2006 Feb;13(2):159-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma.
  • BACKGROUND: Hepatoma-derived growth factor (HDGF) is involved in hepatocarcinogenesis, as well as in liver development and regeneration.
  • This study investigated the correlation of HDGF expression with differentiation and prognosis of hepatocellular carcinoma (HCC).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / diagnosis. Intercellular Signaling Peptides and Proteins / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Japan / epidemiology. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. RNA, Neoplasm / analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16411141.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Neoplasm; 0 / hepatoma-derived growth factor
  •  go-up   go-down


25. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Cheng GY, Wong RS, Lai PP, Leung TW, Tang JC, Chan AS: Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. Int J Mol Med; 2006 May;17(5):945-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines.
  • The cytotoxic activity of this analogue was screened on both Hep3B hepatocellular carcinoma and SK-Hep-1 liver adenocarcinoma cell lines by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay.
  • Morphological changes of hepatoma cell lines were recorded under an inverted microscope.
  • The possible tolerance of these analogues was further investigated using non-malignant haematological bone marrow primary culture.
  • CAN 032 showed a significant cytotoxic response on both hepatoma cell lines in which the potencies were comparable to that of cantharidin.
  • Phase contrast microscopy demonstrated that cell shrinkage, rounding, loss of adherent property and loss of colony-formation ability were induced.
  • [MeSH-minor] Adult. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / physiopathology. Cell Cycle / drug effects. Cell Line, Tumor. Cell Size / drug effects. DNA Fragmentation / drug effects. Dose-Response Relationship, Drug. Female. Humans. Male. Microscopy, Phase-Contrast. Molecular Structure. Thiazoles / chemical synthesis. Thiazoles / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CANTHARIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596285.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CAN 032; 0 / Thiazoles; IGL471WQ8P / Cantharidin
  •  go-up   go-down


26. Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, Aozasa K, Uyama H, Nakamura H, Monden M: Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol; 2007 Jul;14(7):2141-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma.
  • BACKGROUND: Hepatoma-derived growth factor (HDGF) is thought to play an important role in the development and progression of carcinomas.
  • In the present study, association of HDGF expression with recurrence and prognosis of esophageal carcinoma (EC) was examined.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism. Intercellular Signaling Peptides and Proteins / biosynthesis. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473954.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / hepatoma-derived growth factor
  •  go-up   go-down


27. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ: Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci; 2009 Dec;100(12):2249-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many studies on the risk factors and their carcinogenesis in adult hepatocellular carcinoma (HCC) have been reported, they remain poorly understood in childhood HCC.
  • The HBV pre-S2 deletion mutant at nt 4-57 which has a CD8 T-cell epitope could be responsible for the emergence and aggressive outcome of childhood HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Gene Deletion. Hepatitis B Surface Antigens / genetics. Hepatitis B virus / genetics. Liver Neoplasms / etiology. Protein Precursors / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719772.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Protein Precursors; 0 / presurface protein 2, hepatitis B surface antigen
  •  go-up   go-down


28. Hsieh SY, Chen WY, Shih TC, Yeh JY, Jeng JT: Dys-regulation of clusterin in human hepatoma is not associated with tumorigenesis but is secondary to cell response to external tresses. Mol Carcinog; 2005 Jun;43(2):100-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dys-regulation of clusterin in human hepatoma is not associated with tumorigenesis but is secondary to cell response to external tresses.
  • To identify downregulated genes during hepatoma development, we combined the cDNA representational difference analysis (RDA) and reverse Northern blot analysis identifying eight genes.
  • Of interest, the expression of the clusterin gene was either down or upregulated in 8 and 7 out of the 20 hepatoma tissues, respectively.
  • Further analysis revealed that its expression was independent of patients' age, gender, causes of liver disease, tumor size, tumor histological stage, or clinical outcome, but was strongly associated with the methods of hepatectomy procedures.
  • In vitro studies disclosed that the clusterin mRNA was increased twofold in early exponential phase of cell proliferation followed by downregulation in the subsequent quiescence phase, whereas it was rapidly increased up to twelvefold upon UV-induced apoptosis.
  • These results suggest that dys-regulation of the clusterin gene in human hepatoma was most likely due to cellular responses to external stresses especially during the procedures for sample collection rather than any correlation to hepatoma development or progression.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Glycoproteins / genetics. Liver Neoplasms / genetics. Molecular Chaperones / genetics
  • [MeSH-minor] Adult. Aged. Apoptosis. Base Sequence. Blotting, Northern. Cell Line, Tumor. Clusterin. DNA Primers. DNA, Complementary / genetics. Female. Genetic Markers. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Stress, Mechanical. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791650.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLU protein, human; 0 / Clusterin; 0 / DNA Primers; 0 / DNA, Complementary; 0 / Genetic Markers; 0 / Glycoproteins; 0 / Molecular Chaperones; 0 / Neoplasm Proteins
  •  go-up   go-down


29. Dannenberg LO, Edenberg HJ: Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics; 2006 Jul 19;7:181
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation.
  • We hypothesize that many genes in the human hepatoma cell line HepG2 are regulated by DNA methylation and histone deacetylation.
  • Treatment with 5-aza-2'-deoxycytidine (5-aza-dC) to inhibit DNA methylation with and/or Trichostatin A (TSA) to inhibit histone deacetylation should allow us to identify genes that are regulated epigenetically in hepatoma cells.
  • Genes involved in liver processes such as xenobiotic metabolism (CYP3A4, CYP3A5, and CYP3A7) and steroid biosynthesis (CYP17A1 and CYP19A1), and genes encoding CCAAT element-binding proteins (C/EBPalpha, C/EBPbeta, and C/EBPgamma) were affected by 5-aza-dC or the combination.
  • Many of the genes that fall within these groups are also expressed in the developing fetal liver and adult liver.
  • CONCLUSION: Epigenetics play a role in regulating the expression of several genes involved in essential liver processes such as xenobiotic metabolism and steroid biosynthesis in HepG2 cells.
  • Many genes whose expression is normally silenced in these hepatoma cells were re-expressed by 5-aza-dC treatment.
  • DNA methylation may be a factor in restricting the expression of fetal genes during liver development and in shutting down expression in hepatoma cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17174-9 [2211619.001]
  • [Cites] Cell. 1991 Nov 1;67(3):569-79 [1934061.001]
  • [Cites] Cell. 1993 Jan 15;72(1):73-84 [8422685.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8219-23 [8367486.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):158-63 [10322130.001]
  • [Cites] EMBO J. 1994 Feb 15;13(4):851-60 [7906646.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11797-801 [7527544.001]
  • [Cites] Nat Genet. 1995 Aug;10(4):383-93 [7670487.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Annu Rev Genet. 1997;31:493-525 [9442905.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4353-65 [9834242.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3693-702 [9851976.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):148-51 [10322131.001]
  • [Cites] Genes Dev. 1999 Sep 15;13(18):2339-52 [10500090.001]
  • [Cites] J Hepatol. 2004 Nov;41(5):790-8 [15519652.001]
  • [Cites] BMC Genomics. 2003;4(1):4 [12594857.001]
  • [Cites] Mol Biol Rep. 2005 Sep;32(3):141-7 [16172914.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):1856-67 [15958521.001]
  • [Cites] BMC Bioinformatics. 2006;7:49 [16448562.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Jun;30(6):928-37 [16737450.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32260-6 [9405430.001]
  • [Cites] Gene. 1999 Nov 15;240(1):1-12 [10564807.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):1899-910 [10688638.001]
  • [Cites] Nature. 2000 May 25;405(6785):482-5 [10839546.001]
  • [Cites] Trends Biochem Sci. 2000 Dec;25(12):619-23 [11116189.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):383-91 [11279519.001]
  • [Cites] J Cell Biochem. 2001;82(3):357-70 [11500913.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):719-25 [11583633.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):412-7 [11726928.001]
  • [Cites] J Urol. 2002 Jan;167(1):335-8 [11743352.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] EMBO J. 1983;2(3):317-24 [11894944.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2336-45 [11994385.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Methods. 2002 Jun;27(2):150-5 [12095274.001]
  • [Cites] EMBO J. 2002 Sep 2;21(17):4632-40 [12198165.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):586-90 [12629040.001]
  • [Cites] N Engl J Med. 2003 Mar 20;348(12):1134-49 [12646671.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2003 May;3(3):187-99 [12769777.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):599-609 [14992728.001]
  • [Cites] Biochim Biophys Acta. 1970 Nov 11;220(2):307-16 [5487884.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1211-6 [7566983.001]
  • [Cites] Nucleic Acids Res. 1995 Nov 11;23(21):4371-7 [7501458.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2463-7 [8653676.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2508-18 [8665858.001]
  • [Cites] Hum Mol Genet. 1996 Jul;5(7):933-43 [8817327.001]
  • [Cites] Hum Mol Genet. 1996 Nov;5(11):1801-7 [8923009.001]
  • [Cites] Genes Dev. 1997 Aug 15;11(16):2124-36 [9284051.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Trends Genet. 1997 Nov;13(11):444-9 [9385841.001]
  • [Cites] J Biol Chem. 1972 Nov 25;247(22):7365-73 [4674086.001]
  • [Cites] Biochemistry. 1973 Feb 27;12(5):783-91 [4568767.001]
  • [Cites] J Biol Chem. 1975 Jul 10;250(13):4856-63 [168194.001]
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):719-38 [545721.001]
  • [Cites] Science. 1980 Jul 25;209(4455):497-9 [6248960.001]
  • [Cites] Nature. 1979 Dec 6;282(5739):615-6 [233137.001]
  • [Cites] J Biol Chem. 1982 Feb 25;257(4):2041-8 [6173384.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):6993-7 [6209710.001]
  • [Cites] J Steroid Biochem. 1986 Nov;25(5B):749-57 [2433505.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3076-83 [2444874.001]
  • [Cites] DNA. 1987 Oct;6(5):439-48 [3500022.001]
  • [Cites] Arch Biochem Biophys. 1989 Jan;268(1):144-51 [2492179.001]
  • [Cites] In Vitro Cell Dev Biol. 1989 Mar;25(3 Pt 1):267-75 [2466823.001]
  • [Cites] Biochem J. 1990 Jan 1;265(1):23-38 [2405837.001]
  • [Cites] Cell. 1990 Aug 10;62(3):503-14 [1974172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6117-21 [2385586.001]
  • (PMID = 16854234.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R37 AA006460; United States / NIAAA NIH HHS / AA / R37AA06460
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histones; 0 / Hydroxamic Acids; 3X2S926L3Z / trichostatin A; EC 3.5.1.98 / Histone Deacetylases; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC1574318
  •  go-up   go-down


30. Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, Uemoto S: Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol; 2010 Jul;37(1):89-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
  • Hepatocellular carcinoma (HCC) is known to be resistant to chemotherapy.
  • Survivin, a member of the inhibitor of apoptosis proteins, is overexpressed in most cancers but is absent in most normal adult tissue.
  • We confirmed induction of survivin expression in hepatoma in the N-diethylnitrosamine (DEN) induced rat and in the rat hepatoma cell line (K-251).
  • We examined cell proliferation after treatment with cisplatin (CDDP) in the presence and absence of siRNA or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 to suppress survivin or PI3K/Akt, respectively.
  • Expression of survivin was observed primary in the nuclei and in the cytoplasm with immunohistochemistry.
  • Expression of survivin was also observed primarily in the nuclei and in the cytoplasm of the K-251 rat hepatoma cell line.
  • Our results indicate that survivin expression via PI3K contributes to resistance to CDDP-induced apoptosis in a rat hepatoma cell line.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Hepatocellular / genetics. Cisplatin / pharmacology. Drug Resistance, Neoplasm / genetics. Liver Neoplasms, Experimental / genetics. Microtubule-Associated Proteins / genetics. Phosphatidylinositol 3-Kinases / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cells, Cultured. Diethylnitrosamine. Gene Expression Regulation, Neoplastic / drug effects. Male. RNA, Small Interfering / pharmacology. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514400.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Birc5 protein, rat; 0 / Microtubule-Associated Proteins; 0 / RNA, Small Interfering; 3IQ78TTX1A / Diethylnitrosamine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


32. Zhang X, Dong N, Zhang H, You J, Wang H, Ye L: Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. J Lab Clin Med; 2005 Feb;145(2):98-104
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells.
  • In the experiments reported here, we used immunohistochemical methods to study the expression of hTERT and HBV antigens (HBsAg, HBcAg and HBxAg) in 34 cases of HCC and corresponding paratumor tissues, 30 cases of liver cirrhosis, and 6 normal livers.
  • To examine the effect of HBX on hTERT expression and activity in hepatoma cells, we transiently and stably transfected the pCMV-X plasmid cloned HBx gene into H7402 hepatoma cells, then measured the expression of c-Myc and hTERT in these cells with the use of Western-blot analysis.
  • We found that hTERT expression was 67.6%, 73.5%, and 100% in tumor, paratumor, and cirrhosis samples, respectively, but found no hTERT positivity in samples of normal liver.
  • Our data collectively demonstrate that HBX up-regulates the expression and activity of hTERT in hepatoma cells, suggesting that hTERT is associated with tumor development.
  • [MeSH-major] Carcinoma, Hepatocellular / physiopathology. Hepatitis B / physiopathology. Hepatitis B virus / genetics. Liver Neoplasms / physiopathology. Telomerase / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adult. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Humans. Liver Cirrhosis / physiopathology. Liver Cirrhosis / virology. Male. Middle Aged. Proto-Oncogene Proteins c-myc / genetics. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746653.001).
  • [ISSN] 0022-2143
  • [Journal-full-title] The Journal of laboratory and clinical medicine
  • [ISO-abbreviation] J. Lab. Clin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Trans-Activators; 0 / hepatitis B virus X protein; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


33. Ortiz C, Caja L, Sancho P, Bertran E, Fabregat I: Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion. Biochem Pharmacol; 2008 May 15;75(10):1935-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion.
  • FaO rat hepatoma cells show increased levels of the epidermal growth factor receptor (EGFR) ligands, when compared with adult normal hepatocytes, and higher activity of the TNF-alpha converting enzyme (TACE/ADAM17), which is required for EGFR ligand proteolysis and activation.
  • In this work we have analysed the consequences of inhibiting the EGFR in FaO rat hepatoma cells, focusing the attention on autocrine growth and protection from apoptosis.
  • Incubation of cells with glutathione ethyl ester attenuates the apoptosis induced by the combination of doxorubicin and AG1478, which indicates that glutathione depletion is required for an efficient cell death.
  • In conclusion, targeting EGFR combined with other conventional pro-apoptotic drugs should potentially be effective in antineoplastic therapy towards liver cancer.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Caspase 3 / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Cells, Cultured. Glutathione / metabolism. Hepatocytes / drug effects. Hepatocytes / metabolism. Male. Quinazolines. Rats. Rats, Wistar. Reactive Oxygen Species / metabolism. bcl-2-Associated X Protein / metabolism

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18371937.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Bax protein, rat; 0 / Egfr protein, rat; 0 / Quinazolines; 0 / Reactive Oxygen Species; 0 / Tyrphostins; 0 / bcl-2-Associated X Protein; 170449-18-0 / tyrphostin AG 1478; 80168379AG / Doxorubicin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.22.- / Caspase 3; GAN16C9B8O / Glutathione
  •  go-up   go-down


34. Zhu N, Shao Y, Xu L, Yu L, Sun L: Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells. Mol Biol Rep; 2009 Nov;36(8):2075-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells.
  • The Gadd45 family of proteins, which includes alpha, beta, and gamma isoforms, has recently been shown to play a role in the G2/M cell cycle checkpoint in response to DNA damage; however, the mechanisms by which Gadd45 proteins inhibit cell cycle control are not fully understood.
  • Using immunohistochemical analysis, we found that protein expression of Gadd45gamma, but not Gadd45alpha, was down-regulated in hepatocellular carcinoma.
  • We thus investigated possible mechanisms by which Gadd45alpha and Gadd45gamma might differentially induce G2/M arrest in the human hepatoma Hep-G2 cell line.
  • Taken together, these findings suggest that the induction of G2/M arrest by Gadd45alpha or Gadd45gamma involves activation of two distinct signaling pathways in Hep-G2 hepatoma cell lines.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. JNK Mitogen-Activated Protein Kinases / metabolism. Liver Neoplasms / metabolism. MAP Kinase Signaling System. Nuclear Proteins / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Cell Cycle. Down-Regulation. Female. G2 Phase / physiology. Hep G2 Cells. Humans. Immunohistochemistry. Male. Middle Aged. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048389.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GADD45A protein, human; 0 / GADD45G protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


35. Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, Chen CH, Lu SN, Lee CM, Changchien CS, Hu TH: Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer; 2007 Sep 1;121(5):1059-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors.
  • Hepatoma-derived growth factor (HDGF) is a novel growth factor and elevated in several types of cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17487837.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / hepatoma-derived growth factor
  •  go-up   go-down


36. Martínez-Jiménez CP, Gómez-Lechón MJ, Castell JV, Jover R: Underexpressed coactivators PGC1alpha and SRC1 impair hepatocyte nuclear factor 4 alpha function and promote dedifferentiation in human hepatoma cells. J Biol Chem; 2006 Oct 6;281(40):29840-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underexpressed coactivators PGC1alpha and SRC1 impair hepatocyte nuclear factor 4 alpha function and promote dedifferentiation in human hepatoma cells.
  • Hepatocyte nuclear factor 4alpha (HNF4alpha) plays critical roles during liver development and in the transcriptional regulation of many hepatic genes in adult liver.
  • Here we have demonstrated that in human hepatoma HepG2 cells, HNF4alpha is expressed at levels as high as in human liver but its activity on target genes is very low or absent.
  • Altogether, our results suggest that SRC1, and notably PGC1alpha, are key coactivators for the proper function of HNF4alpha in human liver and for an integrative control of multiple hepatic genes involved in metabolism and homeostasis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Down-Regulation / physiology. Heat-Shock Proteins / physiology. Hepatocyte Nuclear Factor 4 / antagonists & inhibitors. Histone Acetyltransferases / physiology. Liver Neoplasms / metabolism. Transcription Factors / physiology
  • [MeSH-minor] Adult. Aged. Cell Differentiation / physiology. Cell Line, Tumor. Female. Homeostasis / physiology. Humans. Liver / metabolism. Male. Middle Aged. Nuclear Receptor Coactivator 1


37. Yu BY, Hu SW, Sun YM, Lee YT, Young TH: Modulating the activities of human mesenchymal stem cells (hMSCs) and C3A/HepG2 hepatoma cells by modifying the surface characteristics of poly(3-hydroxybutyrate-co-3-hydroxyhexnoate) (PHBHHx). J Biomater Sci Polym Ed; 2009;20(9):1275-93
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulating the activities of human mesenchymal stem cells (hMSCs) and C3A/HepG2 hepatoma cells by modifying the surface characteristics of poly(3-hydroxybutyrate-co-3-hydroxyhexnoate) (PHBHHx).
  • In contrast, the behaviors of C3A/HepG2 hepatoma cells presented an opposite outcomes.
  • [MeSH-minor] Adult. Biocompatible Materials / chemistry. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Carbon Dioxide / chemistry. Carcinoma, Hepatocellular / metabolism. Cell Line, Tumor. Cell Proliferation. Cells, Cultured. Hepatoblastoma / metabolism. Humans. L-Lactate Dehydrogenase / metabolism. Liver Neoplasms / metabolism. Surface Properties

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19520012.001).
  • [ISSN] 0920-5063
  • [Journal-full-title] Journal of biomaterials science. Polymer edition
  • [ISO-abbreviation] J Biomater Sci Polym Ed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Caproates; 0 / poly(3-hydroxybutyrate-co-3-hydroxyhexanoate); 142M471B3J / Carbon Dioxide; 14485-07-5 / carboxyl radical; EC 1.1.1.27 / L-Lactate Dehydrogenase; TZP1275679 / 3-Hydroxybutyric Acid
  •  go-up   go-down


38. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact; 2007 May 20;168(1):66-73
Hazardous Substances Data Bank. AFLATOXIN B1 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
  • Although they have several important limitations primary human hepatocytes still represent the in vitro gold standard model for xenobiotic metabolism and toxicity studies.
  • The large use of human liver cell lines either from tumoral origin or obtained by oncogenic immortalisation is prevented by the loss of various liver-specific functions, especially many cytochrome P450 (CYP)-related enzyme activities.
  • We review here recent results obtained with a new human hepatoma cell line, named HepaRG, derived from a human hepatocellular carcinoma.
  • Moreover contrary to other human hepatoma cell lines including HepG2 cells, HepaRG cells express various CYPs (CYP1A2, 2B6, 2C9, 2E1, 3A4) and the nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) at levels comparable to those found in cultured primary human hepatocytes.
  • They also express various other functions such phase 2 enzymes, apical and canalicular ABC transporters and basolateral solute carrier transporters, albumin, haptoglobin as well as aldolase B that is a specific marker of adult hepatocytes.
  • HepaRG cells could represent a surrogate to primary human hepatocytes for xenobiotic metabolism and toxicity studies and even more, a unique model system for analysing genotoxic compounds.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Models, Biological. Xenobiotics / toxicity
  • [MeSH-minor] Aflatoxin B1 / poisoning. Biomarkers / metabolism. Cell Differentiation. Cell Line, Tumor. Cytochrome P-450 Enzyme System / genetics. Cytochrome P-450 Enzyme System / metabolism. Female. Hepatocytes / cytology. Hepatocytes / drug effects. Hepatocytes / metabolism. Humans. Inhibitory Concentration 50. Metabolic Detoxication, Phase I. Metabolic Detoxication, Phase II. RNA, Messenger / analysis. Receptors, Cytoplasmic and Nuclear / genetics. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Steroid / genetics. Receptors, Steroid / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - HepaRG (CVCL_9720) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241619.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / Transcription Factors; 0 / Xenobiotics; 0 / constitutive androstane receptor; 0 / pregnane X receptor; 9035-51-2 / Cytochrome P-450 Enzyme System; 9N2N2Y55MH / Aflatoxin B1
  • [Number-of-references] 23
  •  go-up   go-down


39. Lepourcelet M, Tou L, Cai L, Sawada J, Lazar AJ, Glickman JN, Williamson JA, Everett AD, Redston M, Fox EA, Nakatani Y, Shivdasani RA: Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development; 2005 Jan;132(2):415-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF).
  • Transcripts that decline significantly during intestine development frequently are absent from the adult gut.
  • As an example, hepatoma-derived growth factor (HDGF) mRNA is expressed prominently in early gut tissue, with substantially reduced levels after villous epithelial differentiation.
  • [MeSH-minor] Animals. Base Pair Mismatch. Cell Differentiation. DNA Repair. DNA, Complementary / metabolism. Databases, Genetic. Gene Expression Profiling. Heterogeneous-Nuclear Ribonucleoproteins / metabolism. Humans. In Situ Hybridization. Intestinal Mucosa. Mice. RNA, Messenger / metabolism. RNA, Neoplasm. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Time Factors

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604097.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK61139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Heterogeneous-Nuclear Ribonucleoproteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / hepatoma-derived growth factor
  •  go-up   go-down


40. Fujimoto T, Tomizawa M, Yokosuka O: SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells. Int J Oncol; 2009 Oct;35(4):861-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells.
  • Frizzled (Fz), a receptor of Wnt ligands, plays key roles in liver carcinogenesis.
  • Its expression was analyzed as part of a search for a target of molecular therapy for hepatocellular carcinoma (HCC) and hepatoblastoma (HB).
  • Fz genes were analyzed by RT-PCR in HCC cell lines HLE, HLF, PLC/PRF/5, Huh-7 and Hep3B, HB cell lines Huh-6 and HepG2, HeLa cells, human normal fetal and adult liver.
  • Five days after transfection, cell proliferation was analyzed by MTS assay and cell motility by wound assay with H&E staining.
  • Fz9-siRNA decreased the expression of Fz9 gene in all cell lines.
  • MTS assay showed that Fz9-siRNA significantly suppressed cell proliferation and cell motility in all cell lines.
  • Cleaved caspase-3 did not appear and apoptosis was not observed in any of the cell lines tested.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cell Movement. Cell Proliferation. Frizzled Receptors / metabolism. Liver Neoplasms / metabolism. RNA Interference. RNA, Small Interfering / metabolism. Receptors, G-Protein-Coupled / metabolism
  • [MeSH-minor] Adult. Apoptosis. Blotting, Western. Caspase 3 / metabolism. Cyclin D1 / metabolism. Down-Regulation. HeLa Cells. Humans. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - FZD9 - data and references .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724923.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / FZD3 protein, human; 0 / Frizzled Receptors; 0 / RNA, Small Interfering; 0 / Receptors, G-Protein-Coupled; 136601-57-5 / Cyclin D1; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


41. Yan K, Chen MH, Dai Y, Shen L, Jiang XL: [Results of enhanced ultrasonography in assessing hepatoma treated with radiofrequency ablation]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):41-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of enhanced ultrasonography in assessing hepatoma treated with radiofrequency ablation].
  • METHODS: Eighteen patients with 17 primary hepatocellular carcinoma and 1 hepatic metastasis were studied.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Catheter Ablation. Liver Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771798.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


42. Chen RC, Chang YC, Chen TH, Wu HM, Liou HH: Mortality in adult patients with epilepsy in Taiwan. Epileptic Disord; 2005 Sep;7(3):213-9
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality in adult patients with epilepsy in Taiwan.
  • To investigate mortality in adult patients with epilepsy in Taiwan, a total of 263 patients with epilepsy aged > or = 17 years, referred to the outpatient epilepsy clinic between 1 Jan and 31 December 1991, were prospectively enrolled and followed up until 31 December 2000.
  • One-third of the deaths in patients with age-at-onset between 40-59 years died of liver cirrhosis and hepatoma.
  • Hepatitis B virus infection is endemic in Taiwan, and this is closely associated with liver cirrhosis and hepatoma.
  • Whether anticonvulsants contributed to the hepatotoxicity that led to fatal liver disease in this group needs further investigation.
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Cause of Death. Cohort Studies. Female. Humans. Liver Diseases / complications. Liver Diseases / mortality. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Prospective Studies. Regression Analysis. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162430.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


43. El-Tahir HM, Abouzied MM, Gallitzendoerfer R, Gieselmann V, Franken S: Hepatoma-derived growth factor-related protein-3 interacts with microtubules and promotes neurite outgrowth in mouse cortical neurons. J Biol Chem; 2009 Apr 24;284(17):11637-51
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma-derived growth factor-related protein-3 interacts with microtubules and promotes neurite outgrowth in mouse cortical neurons.
  • Hepatoma-derived growth factor-related proteins (HRP) comprise a family of 6 members, which the biological functions are still largely unclear.
  • Upon maturation HRP-3 relocalizes continuously to the nuclei and in the majority of neurons of adult mice it is located exclusively in the nucleus.
  • This redistribution from neurites to nuclei is also found in embryonic cortical neurons maturing in cell culture.
  • We show that HRP-3 is necessary for proper neurite outgrowth in primary cortical neurons.
  • [MeSH-minor] Amino Acid Sequence. Animals. Brain / embryology. Cell Proliferation. Cytoskeleton / metabolism. Dimerization. Mice. Models, Biological. Molecular Sequence Data. Tubulin / chemistry

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37564-8 [11481329.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8029-38 [10075702.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):583-91 [12134159.001]
  • [Cites] Biochem J. 2002 Sep 1;366(Pt 2):491-500 [12006088.001]
  • [Cites] Cell Mol Life Sci. 2003 Feb;60(2):413-21 [12678504.001]
  • [Cites] Methods Cell Biol. 2003;71:287-304 [12884695.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34691-9 [12807913.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1444-56 [14508832.001]
  • [Cites] Int Rev Cytol. 2003;227:183-219 [14518552.001]
  • [Cites] Neuron. 2003 Oct 9;40(2):209-27 [14556705.001]
  • [Cites] J Neurobiol. 2004 Jan;58(1):18-33 [14598367.001]
  • [Cites] J Neurobiol. 2004 Jan;58(1):34-47 [14598368.001]
  • [Cites] Biochem J. 2004 Feb 15;378(Pt 1):169-76 [14572309.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27320-6 [15140875.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30850-5 [15136563.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50176-80 [15466863.001]
  • [Cites] FEBS J. 2005 Feb;272(3):822-31 [15670162.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):117-22 [16397032.001]
  • [Cites] Protein Sci. 2006 Feb;15(2):314-23 [16384999.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):159-67 [16411141.001]
  • [Cites] BMC Neurosci. 2006;7:6 [16430771.001]
  • [Cites] Nucleic Acids Res. 2006;34(5):1653-65 [16549878.001]
  • [Cites] J Mol Biol. 2006 Jul 21;360(4):760-73 [16793062.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1575-92 [16939976.001]
  • [Cites] J Neurochem. 2006 Oct;99(1):70-83 [16987236.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):609-15 [16934447.001]
  • [Cites] J Mol Biol. 2007 Mar 23;367(2):456-72 [17270212.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):483-96 [17344411.001]
  • [Cites] BMC Mol Biol. 2007;8:101 [17974029.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1617-24 [18024791.001]
  • [Cites] Cell. 2009 Feb 6;136(3):551-64 [19185337.001]
  • [Cites] J Mol Biol. 2009 Mar 6;386(4):938-50 [19162039.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 9;266(1):81-7 [10581169.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):17917-20 [10770920.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2648-57 [10937578.001]
  • [Cites] Nat Neurosci. 2001 Aug;4(8):781-2 [11477421.001]
  • [Cites] J Mol Biol. 2004 Nov 5;343(5):1365-77 [15491618.001]
  • [Cites] Anal Biochem. 1988 Nov 15;175(1):91-5 [3245580.001]
  • [Cites] Int J Dev Biol. 1994 Mar;38(1):13-25 [8074993.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):550-3 [8849730.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):26-32 [9299445.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33118-24 [9407097.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10315-22 [11751870.001]
  • (PMID = 19237540.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hdgfrp3 protein, mouse; 0 / Nuclear Proteins; 0 / Tubulin
  • [Other-IDs] NLM/ PMC2670168
  •  go-up   go-down


44. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol; 2007 Jul 1;222(1):42-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues.
  • Frequently, primary hepatocytes are used as an in vitro model for the liver in vivo.
  • In this study, we characterized the differentiation character of primary human hepatocytes cultured using a highly defined, serum-free two-dimensional sandwich system, one that configures hepatocytes with collagen I as the substratum together with a dilute extracellular matrix (Matrigeltrade mark) overlay combined with a defined serum-free medium containing nanomolar levels of dexamethasone.
  • Whole genome expression profiling enabled direct comparison of liver tissues to hepatocytes and to the hepatoma-derived cell lines, HepG2 and Huh7.
  • The robustness of the primary hepatocyte cultures was reflected by the extent of unchanged expression character when compared directly to liver, with more than 77% of the probe sets unchanged in each of the over-represented categories, representing such genes as C/EBPalpha, HNF4alpha, CYP2D6, and ABCB1.
  • In contrast, HepG2 and Huh7 cells were unchanged from the liver tissues for fewer than 48% and 55% of these probe sets, respectively.
  • Further, hierarchical clustering of the hepatocytes, but not the cell lines, shifted from donor-specific to treatment-specific when the probe sets were filtered to focus on phenobarbital-inducible genes, indicative of the highly differentiated nature of the hepatocytes when cultured in a highly defined two-dimensional sandwich system.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Phenobarbital .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W645-50 [16912992.001]
  • [Cites] Toxicol In Vitro. 2002 Feb;16(1):89-99 [11812644.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1293-303 [11322933.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):219-31 [12011481.001]
  • [Cites] Xenobiotica. 2002 Jun;32(6):505-20 [12160483.001]
  • [Cites] Science. 2002 Oct 11;298(5592):422-4 [12376703.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Mol Endocrinol. 2003 Jul;17(7):1268-82 [12663745.001]
  • [Cites] Drug Metab Dispos. 2003 Aug;31(8):1035-42 [12867492.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):208-22 [12832660.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] Exp Cell Res. 2004 Jan 15;292(2):252-64 [14697333.001]
  • [Cites] Mol Pharmacol. 2004 Mar;65(3):550-7 [14978233.001]
  • [Cites] Genomics. 2004 Apr;83(4):541-9 [15028276.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22250-7 [15004017.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1294-302 [15290872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2161-5 [3353374.001]
  • [Cites] Arch Biochem Biophys. 1993 Feb 15;301(1):103-13 [8442654.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):373-85 [8745335.001]
  • [Cites] Methods Enzymol. 1996;272:388-401 [8791798.001]
  • [Cites] Toxicol Pathol. 1996 Jan-Feb;24(1):48-57 [8839280.001]
  • [Cites] Arch Biochem Biophys. 1997 Jan 15;337(2):275-83 [9016823.001]
  • [Cites] Biochem Pharmacol. 1997 Oct 1;54(7):761-72 [9353130.001]
  • [Cites] Drug Metab Dispos. 1999 Jun;27(6):637-44 [10348791.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):887-94 [10421615.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):909-15 [10421618.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49517-22 [15358766.001]
  • [Cites] Drug Metab Dispos. 2005 Mar;33(3):388-94 [15608134.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):927-34 [15772367.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Reprod Toxicol. 2005 Sep-Oct;20(3):433-40 [15964738.001]
  • [Cites] Toxicology. 2006 Feb 1;218(2-3):205-15 [16337326.001]
  • [Cites] BMC Bioinformatics. 2006;7:49 [16448562.001]
  • [Cites] Mol Pharmacol. 2002 Jan;61(1):1-6 [11752199.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • (PMID = 17512962.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES011387-02; United States / NIEHS NIH HHS / ES / U19 ES011387-05; United States / NIGMS NIH HHS / GM / R01 GM066411-03; United States / NIGMS NIH HHS / GM / R01 GM066411; United States / NIEHS NIH HHS / ES / ES011387-04; United States / NIGMS NIH HHS / GM / GM066411-01; United States / NIEHS NIH HHS / ES / U19 ES011387-05S1; United States / NIGMS NIH HHS / GM / GM066411; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NIEHS NIH HHS / ES / ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387; United States / NIGMS NIH HHS / GM / R01 GM066411-01; United States / NIGMS NIH HHS / GM / GM066411-04; United States / NIEHS NIH HHS / ES / U19 ES011387-04; United States / NIEHS NIH HHS / ES / ES011387-03; United States / NIGMS NIH HHS / GM / R01 GM066411-02; United States / NIEHS NIH HHS / ES / U19 ES11387; United States / NIGMS NIH HHS / GM / GM066411-02; United States / NIEHS NIH HHS / ES / ES011387-05S1; United States / NIEHS NIH HHS / ES / U19 ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387-03; United States / NIEHS NIH HHS / ES / ES011387-05; United States / NIGMS NIH HHS / GM / GM066411-03; United States / NIEHS NIH HHS / ES / U19 ES011387-02; United States / NIGMS NIH HHS / GM / R01 GM066411-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 63231-63-0 / RNA; YQE403BP4D / Phenobarbital
  • [Other-IDs] NLM/ NIHMS243113; NLM/ PMC2974173
  •  go-up   go-down


45. Koneru B, Teperman LW, Manzarbeitia C, Facciuto M, Cho K, Reich D, Sheiner P, Fisher A, Noto K, Goldenberg A, Korogodsky M, Campbell D: A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg; 2005 Apr;241(4):622-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma.
  • OBJECTIVE: To determine utility of practice of chest computed tomography (CCT) and bone scan (BS) in patients with early-stage hepatoma evaluated for transplantation (LT).
  • SUMMARY BACKGROUND DATA: Consensus-based policy mandates routine CCT and BS in LT candidates with hepatoma.
  • METHODS: From January 1999 to December 2002, stages I and II hepatoma patients evaluated at 4 centers were included.
  • Twelve patients were declined listing, 6 from progression of hepatoma but none from CCT or BS findings.
  • Two listed patients were delisted for progression of the hepatoma.
  • Proportion of patients listed, transplanted, clinical and pathologic stage of hepatoma, and recurrence after LT were similar in groups with negative and indeterminate scans.
  • CONCLUSIONS: Positive yield of routine CCT and BS in patients with hepatoma is very low despite substantial charges and potential complications.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Liver Transplantation. Neoplasm Staging / methods. Tomography, X-Ray Computed / utilization
  • [MeSH-minor] Adult. Cohort Studies. Cost-Benefit Analysis. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Predictive Value of Tests. Preoperative Care / methods. Radiography, Thoracic / economics. Radiography, Thoracic / utilization. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome


46. Dunigan JT, Carr BI, Steel JL: Posttraumatic growth, immunity and survival in patients with hepatoma. Dig Dis Sci; 2007 Sep;52(9):2452-9
MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttraumatic growth, immunity and survival in patients with hepatoma.
  • This study was designed to assess the relationship between posttraumatic growth (PTG), immunity, and survival in patients with biopsy-proven hepatocellular carcinoma (HCC).
  • The results of this study suggest that patients with greater PTG scores recover more rapidly from chemotherapy in regards to their white blood cell counts.
  • [MeSH-major] Carcinoma, Hepatocellular. Immunity, Cellular / immunology. Liver Neoplasms. Stress Disorders, Post-Traumatic / complications
  • [MeSH-minor] Adult. Aged. Biopsy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Sex Distribution. Surveys and Questionnaires. Survival Rate. Time Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17417728.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Goulet F, Napa ID, Solomon L, Morin O, Islam N: Modulated expression of a nuclear-associated glycoprotein during normal rat liver development and in various hepatoma cells. Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan;30(1):159-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulated expression of a nuclear-associated glycoprotein during normal rat liver development and in various hepatoma cells.
  • Liver plays a major role in systemic detoxification and drug metabolism.
  • NF-164, a protein of 164 kDa predominantly localized in hepatocyte nuclei, was found to be present in increasing amounts during liver maturation.
  • In addition, fetal rat hepatocytes had ten times, and neonatal five times less of this protein than adult hepatocytes.
  • It was also detected in an albumin producing hepatoma cell line, but not in three other lines that have lost several differentiated functions.
  • NF-164 seems to be liver-specific, since it was not detected in rat brain, spleen, kidney, lung and bovine thymus.
  • It was purified from adult rat hepatocyte nuclei.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Gene Expression Regulation, Developmental / physiology. Hepatocytes / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Age Factors. Animals. Animals, Newborn. Cell Proliferation. Cells, Cultured. Electrophoresis / methods. Electrophoresis, Polyacrylamide Gel / methods. Female. Molecular Weight. Radioimmunodetection / methods. Rats. Rats, Inbred F344. Sequence Analysis, Protein / methods. Subcellular Fractions / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16233943.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-164 protein, rat; 0 / Nuclear Proteins
  •  go-up   go-down


48. Ng SK, Neo SY, Yap YW, Karuturi RK, Loh ES, Liau KH, Ren EC: Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation. Biochem Biophys Res Commun; 2009 Sep 18;387(2):310-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation.
  • Cancer such as hepatocellular carcinoma (HCC) is characterized by complex perturbations in multiple signaling pathways, including the phosphoinositide-3-kinase (PI3K/AKT) pathways.
  • Among the siRNAs tested against the eight known catalytic PI3K isoforms, specific ablation of class II PI3K alpha (PIK3C2alpha) was the most effective in impairing cell growth and this was accompanied by concomitant decrease in PIK3C2alpha mRNA and protein levels.
  • Taken together, these data suggest for the first time that in addition to class I PI3Ks in cancer, class II PIK3C2alpha can modulate HCC cell growth.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cell Proliferation. Liver Neoplasms / pathology. Phosphatidylinositol 3-Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / genetics. Base Sequence. Caspase 3 / metabolism. Class II Phosphatidylinositol 3-Kinases. Female. Humans. Male. Middle Aged. Molecular Sequence Data. RNA, Small Interfering / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19591801.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / Class II Phosphatidylinositol 3-Kinases; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


49. Miura N, Osaki Y, Nagashima M, Kohno M, Yorozu K, Shomori K, Kanbe T, Oyama K, Kishimoto Y, Maruyama S, Noma E, Horie Y, Kudo M, Sakaguchi S, Hirooka Y, Ito H, Kawasaki H, Hasegawa J, Shiota G: A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol; 2010;10:46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel biomarker TERTmRNA is applicable for early detection of hepatoma.
  • BACKGROUNDS: We previously reported a highly sensitive method for serum human telomerase reverse transcriptase (hTERT) mRNA for hepatocellular carcinoma (HCC).
  • METHODS: In 638 subjects including 303 patients with HCC, 89 with chronic hepatitis (CH), 45 with liver cirrhosis (LC) and 201 healthy individuals, we quantified serum hTERTmRNA using the real-time RT-PCR.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Early Detection of Cancer / methods. Liver Neoplasms / diagnosis. RNA, Messenger / genetics. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. ROC Curve. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Stat Med. 1991 Jul;10(7):1075-88 [1876796.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):56-62 [9062581.001]
  • [Cites] Int J Cancer. 1997 Apr 22;74(2):141-7 [9133446.001]
  • [Cites] Br J Cancer. 1997;76(5):628-33 [9303362.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1561-7 [10102626.001]
  • [Cites] Pathol Int. 1999 Jun;49(6):491-9 [10469391.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):1961-5 [10473072.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3205-9 [15867214.001]
  • [Cites] Hepatology. 2006 Jun;43(6):1284-94 [16729333.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):230-5 [16929622.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):853-9 [17094946.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1366-73 [17052260.001]
  • [Cites] Oncol Rep. 2007 Mar;17(3):541-8 [17273731.001]
  • [Cites] Hepatology. 2007 Apr;45(4):968-76 [17393506.001]
  • [Cites] Biochem Pharmacol. 2007 Jun 1;73(11):1703-14 [17321502.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):1207-12 [17465264.001]
  • [Cites] Biol Pharm Bull. 2007 Aug;30(8):1400-6 [17666793.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2304-10 [17713555.001]
  • [Cites] J Leukoc Biol. 2007 Nov;82(5):1174-84 [17715360.001]
  • [Cites] Mol Cell. 2007 Oct 26;28(2):315-27 [17964269.001]
  • [Cites] Eur J Cell Biol. 2007 Dec;86(11-12):763-80 [17198740.001]
  • [Cites] Exp Mol Med. 2007 Oct 31;39(5):641-52 [18059140.001]
  • [Cites] FASEB J. 2008 Feb;22(2):622-32 [17898088.001]
  • [Cites] Hepatology. 2008 Dec;48(6):2047-63 [19003900.001]
  • [Cites] Ann N Y Acad Sci. 2006 May;1067:443-7 [16804024.001]
  • [Cites] J Pathol. 1999 Oct;189(2):213-8 [10547577.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):496-502 [10717526.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3823-6 [11051224.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Sep;15(9):1064-70 [11059939.001]
  • [Cites] Arch Surg. 2000 Nov;135(11):1334-9 [11074892.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Jul;17(7):772-8 [12121507.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1212-7 [12142376.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1647-53 [12324479.001]
  • [Cites] Oncology. 2003;64(4):430-4 [12759542.001]
  • [Cites] Cell. 2003 Jun 27;113(7):881-9 [12837246.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3004-11 [12912949.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1008-13 [12942569.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Oct;18(10):1168-74 [12974904.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1540-51 [14647065.001]
  • [Cites] Cell Transplant. 2003;12(8):897-906 [14763510.001]
  • [Cites] World J Gastroenterol. 2004 Jul 15;10(14):2147-9 [15237456.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):44-50 [15305374.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6622-6 [3413114.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1050-5 [8635122.001]
  • (PMID = 20482774.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2881114
  •  go-up   go-down


50. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology; 2007 Feb;45(2):269-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.
  • Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Liver Transplantation. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Antigens, CD147 / immunology. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Single-Blind Method. Survival Rate. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2007 Jul;13(7):1057-8 [17600354.001]
  • [CommentIn] Hepatology. 2007 Feb;45(2):263-5 [17256762.001]
  • (PMID = 17256759.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BSG protein, human; 0 / alpha-Fetoproteins; 0 / metuximab; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


51. Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Ootao R, Horlad H, Baba Y, Miyase S, Takamori H, Baba H: Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus. Hepatol Res; 2009 May;39(5):525-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus.
  • In patients with no indication for a hepatic resection, the prognosis of adult hepatoblastoma is quite poor.
  • A 54-year-old man with hepatitis C virus-associated liver cirrhosis was initially treated with a hepatic resection for a hepatic tumor, 3 cm in diameter.
  • The tumor consisted of osteoid-like and cartilaginous foci, myxomatous stroma, and poorly differentiated hepatocellular carcinomatous cells and was diagnosed as a mixed epithelial and mesenchymal hepatoblastoma.
  • Two years after the first operation, multicentric hepatocellular carcinomas developed in the remnant liver and were successfully treated with a secondary hepatic resection combined with radio-frequency ablation.
  • To the best of our knowledge, the primary hepatoblastoma was the smallest such tumor reported and this is the first report of a metachronous hepatoblastoma and hepatocellular carcinoma in an adult hepatitis patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207587.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


52. Nishimura T, Azuma T, Yokoyama A, Ochiai H, Saito H, Hibi T: New mechanism of transforming growth factor-beta signaling in hepatoma: Dramatic up-regulation of tumor initiating cells and epidermal growth factor receptor expression. Hepatol Res; 2009 May;39(5):501-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New mechanism of transforming growth factor-beta signaling in hepatoma: Dramatic up-regulation of tumor initiating cells and epidermal growth factor receptor expression.
  • We studied the effect of TGF-beta on tumor-initiating cells (TICs), which are similar in self-renewal and differentiation features to normal adult stem cells.
  • METHODS: We used side population (SP) cells that exclude DNA binding dye Hoechst 33342 to obtain TICs, studied the differences in the kinetics of the SP cell response to TGF-beta treatment between hepatic tumor cell lines, and performed gene analysis.
  • RESULTS: SP cells from all cell lines have higher proliferative ability compared to non-SP cells and they are drug resistant.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261001.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Moffat ID, Boutros PC, Celius T, Lindén J, Pohjanvirta R, Okey AB: microRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol Sci; 2007 Oct;99(2):470-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] microRNAs in adult rodent liver are refractory to dioxin treatment.
  • We used two miRNA array platforms as well as quantitative reverse transcriptase-polymerase chain reaction to measure miRNA levels in wild-type (WT) versus Ahr-null mice, in dioxin-sensitive Long-Evans (L-E; Turku/AB) rats versus dioxin-resistant Han/Wistar (H/W; Kuopio) rats and in rat 5L and mouse Hepa-1 hepatoma cells in culture.
  • Hepatoma cells in culture also exhibited few changes in miRNA levels in response to TCDD.
  • It is unlikely that mRNA downregulation by dioxins is mediated by miRNAs, nor are miRNAs likely to play a significant role in dioxin toxicity in adult rodent liver.
  • [MeSH-major] Liver / drug effects. MicroRNAs / analysis. Tetrachlorodibenzodioxin / toxicity

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698510.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Receptors, Aryl Hydrocarbon; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


54. Yovchev MI, Grozdanov PN, Joseph B, Gupta S, Dabeva MD: Novel hepatic progenitor cell surface markers in the adult rat liver. Hepatology; 2007 Jan;45(1):139-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel hepatic progenitor cell surface markers in the adult rat liver.
  • These cells can differentiate into hepatocytes and cholangiocytes and could be useful for cell and gene therapy applications.
  • In this work, we studied progenitor/oval cell surface markers in the liver of rats subjected to 2-acetylaminofluorene treatment followed by partial hepatectomy (2-AAF/PH) by using rat genome 230 2.0 Array chips and subsequent RT-PCR, immunofluorescent (IF), immunohistochemical (IHC) and in situ hybridization (ISH) analyses.
  • We also studied expression of the identified novel cell surface markers in fetal rat liver progenitor cells and FAO-1 hepatoma cells.
  • Novel cell surface markers in adult progenitor cells included tight junction proteins, integrins, cadherins, cell adhesion molecules, receptors, membrane channels and other transmembrane proteins.
  • From the panel of 21 cell surface markers, 9 were overexpressed in fetal progenitor cells, 6 in FAO-1 cells and 6 are unique for the adult progenitors (CD133, claudin-7, cadherin 22, mucin-1, ros-1, Gabrp).
  • The specificity of progenitor/oval cell surface markers was confirmed by ISH and double IF analyses.
  • Moreover, study of progenitor cells purified with Ep-CAM antibodies from D-galactosamine injured rat liver, a noncarcinogenic model of progenitor cell activation, verified that progenitor cells expressed these markers.
  • CONCLUSION: We identified novel cell surface markers specific for hepatic progenitor/oval cells, which offers powerful tool for their identification, isolation and studies of their physiology and pathophysiology.
  • Our studies also reveal the mesenchymal/epithelial phenotype of these cells and the existence of species diversity in the hepatic progenitor cell identity.
  • [MeSH-major] Liver / cytology. Liver / metabolism. Membrane Proteins / genetics. Membrane Proteins / metabolism. Stem Cells / metabolism
  • [MeSH-minor] 2-Acetylaminofluorene. Animals. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Cell Line, Tumor. Female. Gene Expression Profiling. Immunohistochemistry. Male. Pregnancy. Rats. Rats, Inbred F344. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. 2-ACETYLAMINOFLUORENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187413.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK59321
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Membrane Proteins; 9M98QLJ2DL / 2-Acetylaminofluorene
  •  go-up   go-down


55. Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L: Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl; 2009 Feb;15(2):169-76
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria.
  • Hepatocellular carcinoma (HCC) is a highly vascular tumor.
  • VEGF mediates its angiogenic effects through multiple receptors including VEGF receptor 2 (VEGFr2, KDR/FLK-1), The distribution and clinical significance of VEGFr2 expression in HCC and cirrhotic liver in the setting of liver transplantation have not been tissue site specific evaluated.
  • Immunohistochemical staining for VEGFr2 was performed in 78 liver explants from patients with HCC undergoing liver transplantation.
  • VEGFr2 levels in HCC were significantly increased compared to adjacent, nontumorous cirrhotic liver areas (P < 0.05).
  • However, VEGFr2 levels were significantly higher in the arteries of non-tumorous liver in patients beyond Milan criteria (P < 0.05).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Liver Cirrhosis / genetics. Liver Neoplasms / genetics. Vascular Endothelial Growth Factor Receptor-2 / biosynthesis
  • [MeSH-minor] Adult. Female. Gene Expression. Humans. Male. Up-Regulation

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 AASLD.
  • (PMID = 19177438.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


56. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY: Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol; 2005 Aug 14;11(30):4655-60
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.
  • AIM: To investigate the clinical values of serum free insulin-like growth factor II (IGF-II) levels and IGF-II mRNA in hepatocellular carcinoma (HCC) tissues and peripheral blood for diagnosis of HCC and monitoring of extrahepatic metastasis.
  • METHODS: Total RNAs were extracted from HCC tissues or peripheral blood mononuclear cells from patients with HCC, liver diseases devoid of cancer, non-hepatic tumors, and healthy controls, respectively.
  • Serum free IGF-II levels in patients with different liver diseases were analyzed by an enzyme-linked immunosorbent assay.
  • The serum free IGF-II levels were significantly higher in HCC than those in chronic hepatitis or liver cirrhosis.
  • The positive frequency of circulating IGF-II mRNA was 34.2% in HCC, no amplified fragment was found in other liver diseases, extrahepatic tumors, and normal controls, respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Insulin-Like Growth Factor II / genetics. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Case-Control Studies. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Molecular Sequence Data

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094705.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 67763-97-7 / Insulin-Like Growth Factor II
  • [Other-IDs] NLM/ PMC4615406
  •  go-up   go-down


57. Polido WT Jr, Lee KH, Tay KH, Wong SY, Singh R, Leong SO, Tan KC: Adult living donor liver transplantation in Singapore: the Asian centre for liver diseases and transplantation experience. Ann Acad Med Singapore; 2007 Aug;36(8):623-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult living donor liver transplantation in Singapore: the Asian centre for liver diseases and transplantation experience.
  • INTRODUCTION: Living donor liver transplantation (LDLT) has progressed dramatically in Asia due to the scarcity of cadaver donors and is increasingly performed in Singapore.
  • The authors present their experience with adult LDLT.
  • MATERIALS AND METHODS: Adult LDLTs performed at the Asian Centre for Liver Diseases and Transplantation, Singapore from 20 April 2002 until 20 March 2006 were reviewed.
  • The majority were chronic liver failure while 14% were acute.
  • The most common indication for LDLT was end-stage liver disease due to hepatitis B virus.
  • A total of 22 patients with hepatoma were transplanted and overall 1-year disease specific survival was 94.4%.
  • The mean model for end-stage liver disease (MELD) score was 17.4 +/- 9.4 (range, 6 to 40).
  • CONCLUSION: The study demonstrates that LDLT can be done safely with good results for a variety of liver diseases.
  • [MeSH-major] Liver Transplantation. Living Donors. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Female. Hospitals, Special. Humans. Male. Medical Audit. Middle Aged. Perioperative Nursing. Singapore / epidemiology. Survival Rate


58. Marikawa Y, Fujita TC, Alarcón VB: Heterogeneous DNA methylation status of the regulatory element of the mouse Oct4 gene in adult somatic cell population. Cloning Stem Cells; 2005;7(1):8-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneous DNA methylation status of the regulatory element of the mouse Oct4 gene in adult somatic cell population.
  • Bisulfite analysis showed that the regulatory element was unmethylated in P19 embryonal carcinoma cells, which robustly express Oct4.
  • By contrast, the regulatory element was distinctly methylated in somatic cells, including cell lines, such as NIH3T3 embryonic fibroblast and Hepa1-6 hepatoma, as well as tissues from the adult body, such as liver, spleen, and cumulus cells.
  • However, we found that the extent of methylation was considerably heterogeneous among the alleles in the adult somatic cells.
  • These results raise the possibility that the epigenetic status of Oct4 is heterogeneous among a population of somatic cells, which may affect the efficiency of Oct4 reactivation after somatic cell nuclear transfer.
  • [MeSH-minor] Alleles. Animals. Cell Line, Tumor. Cell Nucleus / metabolism. CpG Islands. Female. Fibroblasts / metabolism. Genes, Reporter. Humans. Luciferases / metabolism. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Models, Genetic. NIH 3T3 Cells. Octamer Transcription Factor-3. Plasmids / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sulfites / pharmacology. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996113.001).
  • [ISSN] 1536-2302
  • [Journal-full-title] Cloning and stem cells
  • [ISO-abbreviation] Cloning Stem Cells
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR 16467
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / Pou5f1 protein, mouse; 0 / Sulfites; 0 / Transcription Factors; EC 1.13.12.- / Luciferases
  •  go-up   go-down


59. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC: Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One; 2007 Aug 15;2(8):e753
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic infection with hepatitis B virus (HBV) arising in childhood is associated with hepatocellular carcinoma in adult life.
  • Between 1986 and 1990, approximately 120,000 Gambian newborns were enrolled in a randomised controlled trial to assess the effectiveness of infant HBV vaccination on the prevention of hepatocellular carcinoma in adulthood.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / virology. Child. Female. Gambia. Humans. Infant. Liver Neoplasms / etiology. Liver Neoplasms / virology. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 12;355(9203):561-5 [10683019.001]
  • [Cites] J Infect Dis. 2006 Jun 1;193(11):1528-35 [16652281.001]
  • [Cites] Pediatrics. 2001 Apr;107(4):626-31 [11335734.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):569 [12228132.001]
  • [Cites] Scand J Infect Dis. 2002;34(8):610-4 [12238579.001]
  • [Cites] Vaccine. 2002 Oct 4;20(29-30):3472-6 [12297392.001]
  • [Cites] Pediatr Infect Dis J. 2003 Feb;22(2):157-63 [12586980.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5782-7 [2822233.001]
  • [Cites] J Med Virol. 1988 Apr;24(4):377-84 [3367136.001]
  • [Cites] Lancet. 1991 Mar 30;337(8744):747-50 [1672389.001]
  • [Cites] J Hepatol. 1994 Aug;21(2):250-4 [7989718.001]
  • [Cites] J Infect Dis. 1997 Jun;175(6):1494-7 [9180192.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):933-7 [9564478.001]
  • [Cites] Vaccine. 1998 Apr;16(6):624-9 [9569474.001]
  • [Cites] J Infect Dis. 1999 Feb;179(2):489-92 [9878036.001]
  • [Cites] Vaccine. 1999 Apr 23;17(17):2162-5 [10367949.001]
  • [Cites] Vaccine. 1999 Jun 4;17(20-21):2661-6 [10418916.001]
  • [Cites] Vaccine. 1999 Aug 6;17(23-24):2946-50 [10462228.001]
  • [Cites] Vaccine. 2005 Dec 30;23(50):5792-7 [16303217.001]
  • [Cites] J Clin Virol. 2005 Dec;34 Suppl 1:S1-3 [16461208.001]
  • [Cites] Vaccine. 2000 Nov 22;19(7-8):877-85 [11115711.001]
  • (PMID = 17710152.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U190071425; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Other-IDs] NLM/ PMC1940311
  • [General-notes] NLM/ Original DateCompleted: 20070822
  •  go-up   go-down


60. Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP: Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One; 2010 Jun 29;5(6):e11367
eagle-i research resources. PMID 20614008 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma.
  • BACKGROUND: Hydrodynamic injection is an effective method for DNA delivery in mouse liver and is being translated to larger animals for possible clinical use.
  • METHODOLOGY/PRINCIPAL FINDINGS: To study whether hydrodynamic delivery alone, or in conjunction with delivery of phiC31 integrase for long-term transgene expression, could facilitate tumor formation, we used a transgenic mouse model in which sustained induction of the human C-MYC oncogene in the liver was followed by hydrodynamic injection.
  • In contrast, when active or inactive phiC31 integrase and donor plasmid were supplied to the mouse liver, the median tumor latency was 153 days, similar to mice receiving no injection.
  • However, in groups lacking phiC31 integrase, hydrodynamic injection appeared to contribute to C-MYC-induced hepatocellular carcinoma in adult mice.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2005 Oct;12(4):763-71 [16084128.001]
  • [Cites] Methods Mol Biol. 2005;308:99-106 [16082029.001]
  • [Cites] J Mol Biol. 2006 Mar 17;357(1):28-48 [16414067.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Gene Ther. 2006 Aug;13(15):1188-90 [16672982.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11730-5 [16864781.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):871-6 [16942446.001]
  • [Cites] Nucleic Acids Res. 2006;34(21):6298-304 [17098929.001]
  • [Cites] Curr Gene Ther. 2006 Dec;6(6):633-45 [17168696.001]
  • [Cites] Hum Gene Ther. 2006 Nov;17(11):1077-94 [17069535.001]
  • [Cites] Science. 2007 Jul 27;317(5837):477 [17656716.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6 [17785413.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1866-75 [17991809.001]
  • [Cites] Gene Ther. 2008 Mar;15(6):452-62 [18004400.001]
  • [Cites] Cancer Gene Ther. 2008 Apr;15(4):225-30 [18259214.001]
  • [Cites] Mol Ther. 2008 Jun;16(6):1098-104 [18398428.001]
  • [Cites] PLoS One. 2008;3(6):e2493 [18560566.001]
  • [Cites] Lymphat Res Biol. 2008;6(3-4):149-54 [19093787.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):112-20 [19002165.001]
  • [Cites] Mol Ther. 2009 Mar;17(3):491-9 [19156134.001]
  • [Cites] BMC Biotechnol. 2009;9:31 [19341467.001]
  • [Cites] Mol Ther. 2010 Jan;18(1):161-70 [19844192.001]
  • [Cites] Gene Ther. 2010 Feb;17(2):217-26 [19847205.001]
  • [Cites] Mol Ther. 2010 Jul;18(7):1346-56 [20424600.001]
  • [Cites] Mol Biol Rep. 2010 Jul;37(6):2809-16 [19757154.001]
  • [Cites] Hum Gene Ther. 2010 Oct;21(10):1287-97 [20497035.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3926-34 [11359900.001]
  • [Cites] Nat Biotechnol. 2002 Nov;20(11):1124-8 [12379870.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):R425-7 [15182690.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Mod Pathol. 1996 Feb;9(2):95-8 [8657726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Hum Gene Ther. 1999 Jul 1;10(10):1735-7 [10428218.001]
  • [Cites] Gene Ther. 1999 Jul;6(7):1258-66 [10455434.001]
  • [Cites] Oncology. 1999;57(2):157-63 [10461064.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] Mol Ther. 2005 Mar;11(3):399-408 [15727936.001]
  • [Cites] Mol Ther. 2005 May;11(5):695-706 [15851008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):419-24 [16387861.001]
  • (PMID = 20614008.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009302; United States / NCI NIH HHS / CA / CA89305-01A1; United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA034233; United States / NHLBI NIH HHS / HL / R01 HL068112; United States / NCI NIH HHS / CA / R01 CA089305; United States / NHLBI NIH HHS / HL / HL068112; United States / NHLBI NIH HHS / HL / R56 HL068112; United States / NCI NIH HHS / CA / CA09302
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2894073
  •  go-up   go-down


61. Liu J, Xie Y, Merrick BA, Shen J, Ducharme DM, Collins J, Diwan BA, Logsdon D, Waalkes MP: Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver. Toxicol Appl Pharmacol; 2006 Jun 15;213(3):216-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver.
  • Our prior work shows that in utero arsenic exposure alone is a complete transplacental carcinogen, producing hepatocellular carcinoma in adult male offspring but not in females.
  • The dermal application of TPA (2 mug/0.1 ml acetone, twice/week for 21 weeks) after transplacental arsenic did not further increase arsenic-induced liver tumor formation in adult males but significantly increased liver tumor formation in adult females.
  • Thus, for comparison, liver tumors and normal liver samples taken from adult male and female mice at necropsy were analyzed for aberrant gene/protein expression by microarray, real-time RT-PCR and Western blot analysis.
  • Arsenic/TPA treatment resulted in increased expression of alpha-fetoprotein, k-ras, c-myc, estrogen receptor-alpha, cyclin D1, cdk2na, plasminogen activator inhibitor-1, cytokeratin-8, cytokeratin-18, glutathione S-transferases and insulin-like growth factor binding proteins in liver and liver tumors from both male and female mice.
  • Alterations in these gene products were associated with arsenic/TPA-induced liver tumors, regardless of sex.
  • Thus, transplacental arsenic plus postnatal TPA exposure induced similar aberrant gene expression patterns in male and female mouse liver, which are persistent and potentially important to the mechanism of arsenic initiation of hepatocarcinogenesis.
  • [MeSH-major] Arsenic / toxicity. Gene Expression Regulation / drug effects. Liver / drug effects. Liver Neoplasms / metabolism. Prenatal Exposure Delayed Effects. Tetradecanoylphorbol Acetate / toxicity


62. Nagata-Tsubouchi Y, Ido A, Uto H, Numata M, Moriuchi A, Kim I, Hasuike S, Nagata K, Sekiya T, Hayashi K, Tsubouchi H: Molecular mechanisms of hereditary persistence of alpha-fetoprotein (AFP) in two Japanese families A hepatocyte nuclear factor-1 site mutation leads to induction of the AFP gene expression in adult livers. Hepatol Res; 2005 Feb;31(2):79-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms of hereditary persistence of alpha-fetoprotein (AFP) in two Japanese families A hepatocyte nuclear factor-1 site mutation leads to induction of the AFP gene expression in adult livers.
  • alpha-Fetoprotein (AFP) is produced abundantly in fetal liver but is hardly detectable in adults.
  • This substitution in the AFP promoter significantly stimulated its transcriptional activity in human hepatoma cells, regardless of their prior AFP production.
  • The variant-type AFP promoter was also active in adult mouse livers in vivo.
  • Additionally, overexpression of HNF-1alpha stimulated the activity of both the wild- and variant-type AFP promoters in hepatoma cells.
  • These results indicate that an HNF-1 binding site mutation leads to induction of the AFP gene expression in adult liver, and suggest that competition between HNF-1 and NF-I in this region is involved in transcriptional regulation of the AFP gene during hepatic development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716018.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


63. Okudaira T, Tomita M, Uchihara JN, Matsuda T, Ishikawa C, Kawakami H, Masuda M, Tanaka Y, Ohshiro K, Takasu N, Mori N: NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway. Mol Cancer Ther; 2006 Mar;5(3):704-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway.
  • Adult T-cell leukemia (ATL) is caused by human T-cell leukemia virus type I (HTLV-I) and remains incurable.
  • NIK-333, a novel synthetic retinoid, prevents the recurrence of human hepatoma after surgical resection of primary tumors.
  • We explored the effects of NIK-333 on HTLV-I-infected T-cell lines and ATL cells.
  • NIK-333 inhibited cell proliferation, induced G1 arrest, and resulted in massive apoptosis in all tested HTLV-I-infected T-cell lines and ATL cells, whereas little effect was observed on normal peripheral blood mononuclear cells.
  • Further analysis showed that NIK-333 inactivated nuclear factor-kappaB in HTLV-I-infected T-cell lines.
  • In animal studies, treatment with NIK-333 (100 mg/kg given orally every other day) produced partial inhibition of growth of tumors of a HTLV-I-infected T-cell line transplanted s.c. in severe combined immunodeficient mice.
  • [MeSH-major] HTLV-I Infections / drug therapy. Human T-lymphotropic virus 1. Leukemia, T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. NF-kappa B / antagonists & inhibitors. Retinoids / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Transformed. Cell Line, Tumor. Cyclin D1 / metabolism. Cyclin D2. Cyclins / metabolism. Down-Regulation. Female. Humans. Inhibitor of Apoptosis Proteins / metabolism. Mice. Mice, Inbred Strains. Signal Transduction. T-Lymphocytes / virology. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546985.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 0 / Retinoids; 0 / X-Linked Inhibitor of Apoptosis Protein; 11ALM7A4RV / (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid; 136601-57-5 / Cyclin D1
  •  go-up   go-down


64. Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR: Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci; 2009 Nov;112(1):229-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells.
  • Time course and dose-response studies were conducted in HL1-1 cells, a human liver cell line with stem cell-like characteristics, to assess the differential gene expression elicited by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) compared with other established models.
  • Comparative analysis of HL1-1 differential gene expression to human HepG2 data identified 74 genes with comparable temporal expression profiles including 12 putative primary responses.
  • Furthermore, comparative analysis of HL1-1 cells with mouse Hepa1c1c7 hepatoma cell lines and C57BL/6 hepatic tissue identified 18 and 32 commonly regulated orthologous genes, respectively, with functions associated with signal transduction, transcriptional regulation, metabolism and transport.
  • [MeSH-major] Gene Expression Profiling. Liver / drug effects. Receptors, Aryl Hydrocarbon / physiology. Stem Cells / drug effects. Tetrachlorodibenzodioxin / toxicity

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1129-42 [11007951.001]
  • [Cites] Regul Toxicol Pharmacol. 2000 Aug;32(1):56-67 [11029269.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):17-36 [11134541.001]
  • [Cites] Toxicol Sci. 2001 Sep;63(1):65-73 [11509745.001]
  • [Cites] Toxicol In Vitro. 2001 Dec;15(6):741-53 [11698176.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):153-60 [12052653.001]
  • [Cites] Nat Rev Genet. 2002 Aug;3(8):579-88 [12154381.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):207-8 [12700407.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):542-53 [12815380.001]
  • [Cites] Nature. 2003 Aug 21;424(6951):870-2 [12931155.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):361-9 [15093282.001]
  • [Cites] Mutat Res. 2004 May 18;549(1-2):79-99 [15120964.001]
  • [Cites] Toxicol Sci. 2004 Jun;79(2):214-23 [15014205.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):4512-23 [15328365.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 27;321(3):707-15 [15358164.001]
  • [Cites] J Biopharm Stat. 2004 Aug;14(3):647-70 [15468757.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1177-82 [9214600.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:755-60 [9599727.001]
  • [Cites] Bull Environ Contam Toxicol. 1998 Nov;61(5):557-68 [9841714.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):1078-83 [15513988.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):1048-63 [15800033.001]
  • [Cites] Toxicol Sci. 2005 Oct;87(2):508-19 [16049271.001]
  • [Cites] Toxicol Sci. 2006 Apr;90(2):558-68 [16403854.001]
  • [Cites] BMC Genomics. 2006;7:80 [16611356.001]
  • [Cites] BMC Genomics. 2006;7:217 [16934159.001]
  • [Cites] Mol Nutr Food Res. 2006 Oct;50(10):897-907 [16977593.001]
  • [Cites] Toxicol Sci. 2006 Dec;94(2):398-416 [16960034.001]
  • [Cites] Toxicology. 2007 Feb 28;231(1):1-10 [17208344.001]
  • [Cites] Pharmacogenomics. 2007 Mar;8(3):287-91 [17324117.001]
  • [Cites] Toxicol Sci. 2007 Jul;98(1):5-38 [17569696.001]
  • [Cites] Biochem Pharmacol. 2007 Aug 1;74(3):496-503 [17568565.001]
  • [Cites] Toxicol Sci. 2008 Mar;102(1):61-75 [18042819.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):769-77 [18089838.001]
  • [Cites] Toxicol Sci. 2008 Jun;103(2):285-97 [18343893.001]
  • (PMID = 19684285.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Aryl Hydrocarbon; DO80M48B6O / Tetrachlorodibenzodioxin
  • [Other-IDs] NLM/ PMC2769060
  •  go-up   go-down


65. Zhou Y, Zhou N, Fang W, Huo J: Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol; 2010;5:58
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer.
  • BACKGROUND: Hepatoma-derived growth factor (HDGF) is involved in the hepatocarcinogenesis.
  • In this study, we investigated the HDGF expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic features, including the survival of patients with HCC.
  • Furthermore, we examined the biological processes regulated by HDGF during the development of using HepG2 cell line as a model system.
  • METHODS: We used immunohistochemistry to compare HDGF protein expression in HCC and normal liver tissues and further analyze the HDGF protein expression in clinicopathologically characterized 137 HCC cases.
  • Following the successful establishment of stable cells, we examined in vitro cell growth by MTT assay, anchorage-independent growth by soft-agar colony formation assay and cell migration/invasion by transwell and boyden chamber assay.
  • RESULTS: Protein expression level of HDGF was markedly higher in HCC tissues than that in the normal liver tissues(P = 0.011).
  • Compared to the parental and control shRNA-transfected (shCtrl) HepG2 cells, the shHDGF cells exhibited significantly reduced in vitro cell growth, anchorage-independent growth, cell migration and invasion (p < 0.05).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Liver Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Asian Continental Ancestry Group. Cell Movement. Cell Proliferation. China. Female. Hep G2 Cells. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. RNA Interference. Time Factors. Transfection. Tumor Burden. Up-Regulation. Xenograft Model Antitumor Assays. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5714-7 [11479204.001]
  • [Cites] Mol Cancer Ther. 2009 May;8(5):1106-12 [19435872.001]
  • [Cites] Clin Chim Acta. 2001 Nov;313(1-2):15-9 [11694234.001]
  • [Cites] Dev Dyn. 2001 Nov;222(3):450-8 [11747079.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10315-22 [11751870.001]
  • [Cites] Hepatology. 2002 Dec;36(6):1519-27 [12447878.001]
  • [Cites] Curr Drug Targets. 2003 Jul;4(5):367-71 [12816346.001]
  • [Cites] Cancer Sci. 2003 Dec;94(12):1034-41 [14662017.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1194-201 [14751852.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27320-6 [15140875.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3230-7 [15310766.001]
  • [Cites] Clin Chim Acta. 1989 Aug 31;183(3):273-84 [2553304.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):25143-9 [7929202.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1208-19 [9739055.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1075-80 [15870924.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):18-23 [16397209.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):159-67 [16411141.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):674-87 [16929323.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6043-8 [17062679.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2141-9 [17473954.001]
  • [Cites] Arch Iran Med. 2007 Jul;10(3):361-71 [17604475.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1059-65 [17487837.001]
  • [Cites] Mol Cancer. 2008;7:21 [18282277.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1043-52 [18553387.001]
  • [Cites] J Transl Med. 2008;6:32 [18570662.001]
  • [Cites] J Transl Med. 2008;6:55 [18834541.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2120-7 [18823380.001]
  • [Cites] BMC Cancer. 2009;9:17 [19144156.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1811-9 [19107935.001]
  • [Cites] Dig Dis. 2009;27(2):80-92 [19546545.001]
  • [Cites] Int J Cancer. 2009 Oct 15;125(8):1894-901 [19610068.001]
  • [Cites] Mol Cancer. 2009;8:64 [19686584.001]
  • [Cites] Mol Cancer. 2009;8:76 [19778454.001]
  • [Cites] Mol Cancer. 2010;9:78 [20398343.001]
  • [Cites] BMC Cancer. 2010;10:270 [20534121.001]
  • [Cites] BMC Cancer. 2010;10:317 [20569442.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37564-8 [11481329.001]
  • (PMID = 20846397.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / hepatoma-derived growth factor
  • [Other-IDs] NLM/ PMC2949719
  •  go-up   go-down


66. Wong LL, Kindle K, Limm B: Racial disparities in Pacific Islanders undergoing renal transplant evaluation. Hawaii Med J; 2009 Mar;68(2):30-3
MedlinePlus Health Information. consumer health - Native Hawaiian and Pacific Islander Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Hawaii / epidemiology. Humans. Kidney Failure, Chronic / epidemiology. Kidney Failure, Chronic / ethnology. Male. Middle Aged. Retrospective Studies. Waiting Lists. Young Adult

  • MedlinePlus Health Information. consumer health - Health Disparities.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385374.001).
  • [ISSN] 0017-8594
  • [Journal-full-title] Hawaii medical journal
  • [ISO-abbreviation] Hawaii Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Charalabopoulos K, Peschos D, Zoganas L, Bablekos G, Golias C, Charalabopoulos A, Stagikas D, Karakosta A, Papathanasopoulos A, Karachalios G, Batistatou A: Alterations in arterial blood parameters in patients with liver cirrhosis and ascites. Int J Med Sci; 2007;4(2):94-7
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in arterial blood parameters in patients with liver cirrhosis and ascites.
  • We studied 49 cases of liver cirrhosis (LC) with ascites compared to 50 normal controls.
  • Complications were: upper gastrointestinal bleeding 24 (48.97), hepatic encephalopathy 20 (40.81%), gastritis 28 (57.14%), hepatoma 5 (10.2%), renal hepatic syndrome 2 (4.01%), HbsAg (+) 24 (48.97%), and hepatic pleural effusions 7 (14.28%).
  • As a result, pulmonary resistance is impaired and patients more likely succumb to infections and adult respiratory distress syndrome.
  • [MeSH-major] Acid-Base Imbalance / etiology. Arteries / metabolism. Ascites / blood. Liver Cirrhosis / blood. Oxygen / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carbon Dioxide / blood. Female. Hepatopulmonary Syndrome / etiology. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Jan;46(1):1-4 [10601042.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):2994-9 [10520858.001]
  • [Cites] Hepatology. 2000 Oct;32(4 Pt 1):859-65 [11003635.001]
  • [Cites] J Hepatol. 2001 May;34(5):651-7 [11434610.001]
  • [Cites] Gastroenterology. 2003 Oct;125(4):1042-52 [14517788.001]
  • [Cites] Am J Med. 1972 Dec;53(6):715-22 [4564239.001]
  • [Cites] Br Med J. 1972 Dec 16;4(5841):639-43 [4645896.001]
  • [Cites] Gastroenterology. 1977 Aug;73(2):279-84 [873129.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):514-20 [6693014.001]
  • [Cites] Mayo Clin Proc. 1985 Jun;60(6):407-18 [3889511.001]
  • [Cites] Hepatology. 1989 Jun;9(6):808-14 [2714733.001]
  • [Cites] Am J Med. 1991 Jun;90(6):693-700 [1904192.001]
  • [Cites] Gastroenterology. 1993 Apr;104(4):1139-45 [8462804.001]
  • [Cites] Indian J Gastroenterol. 1993 Apr;12(2):36-40 [8340139.001]
  • [Cites] J Hepatol. 1994 Apr;20(4):494-9 [8051388.001]
  • [Cites] Gastroenterology. 1995 Oct;109(4):1283-8 [7557096.001]
  • [Cites] Cardiovasc Intervent Radiol. 1997 Mar-Apr;20(2):120-4 [9030502.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1284-9 [9098014.001]
  • [Cites] Eur Respir J. 1997 Jul;10(7):1622-30 [9230257.001]
  • [Cites] J Hepatol. 1997 Sep;27(3):492-5 [9314126.001]
  • [Cites] Eur Respir J. 1998 May;11(5):1153-66 [9648972.001]
  • [Cites] Liver. 1998 Aug;18(4):239-44 [9766818.001]
  • [Cites] Clin Sci (Lond). 1999 May;96(5):475-81 [10209079.001]
  • [Cites] J Hepatol. 1999 May;30(5):882-9 [10365816.001]
  • [Cites] Wien Klin Wochenschr. 1999 May 7;111(9):339-47 [10407994.001]
  • [Cites] Rev Esp Enferm Dig. 1999 Aug;91(8):559-68 [10491488.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Apr;15(4):412-6 [10824886.001]
  • (PMID = 17396160.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC1838824
  •  go-up   go-down


68. Zhou SJ, Xu SF, Zhang HQ, Liu ZD: [Expression of HDGF and its implication in stage I non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Dec;29(12):927-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of HDGF and its implication in stage I non-small cell lung cancer].
  • OBJECTIVE: To evaluate the expression of HDGF and its implication in patients who undergone radical resection for stage I non-small cell lung cancer.
  • Expresson of HDGF was closely related to histological classification, and the expression in adenocarcinoma was much stronger than that in squamous cell cancers (P = 0.001), but not related to other clinicopathological factors.
  • CONCLUSION: HDGF expression is upgraded in postoperative stage I non-small cell lung cancer patients.
  • HDGF may play an important role on carcinogenesis and development of stage I NSCLC through promoting cell proliferation and neoangiogenesis of the tumor.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Ki-67 Antigen / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / methods. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478933.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A; 0 / hepatoma-derived growth factor
  •  go-up   go-down


69. Lau CI, Wang HC, Hsu WC: Hypoglycemic encephalopathy as the initial presentation of hepatic tumor: a case report. Neurologist; 2010 May;16(3):206-7
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A previously healthy 32-year-old man presenting with acute change in consciousness was found to have hepatoma related hypoglycemia.
  • CONCLUSION: This case highlights the importance of a hepatic evaluation in, otherwise, unexplained hypoglycemic coma in high prevalence areas of hepatocellular carcinoma such as the Asian-Pacific region.
  • [MeSH-major] Brain Diseases, Metabolic / etiology. Brain Diseases, Metabolic / physiopathology. Carcinoma, Hepatocellular / complications. Hypoglycemia / etiology. Hypoglycemia / physiopathology. Liver Neoplasms / complications
  • [MeSH-minor] Adult. Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Blood Glucose / metabolism. Brain / metabolism. Brain / physiopathology. Glucose / therapeutic use. Hepatitis B / complications. Hepatitis B / ethnology. Humans. Male. Prognosis. Taiwan / epidemiology. Taiwan / ethnology. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatic encephalopathy.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445433.001).
  • [ISSN] 2331-2637
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Glucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


70. Gondeau C, Pichard-Garcia L, Maurel P: Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacol Ther; 2009 Oct;124(1):1-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many different models based on different forms of virions and hepatoma or other cell types have been described including virus-like particles, pseudotyped particles, subgenomic and full length replicons, virion productive replicons, immortalised hepatocytes, fetal and adult primary human hepatocytes.
  • This review focuses on these different cellular models, their advantages and disadvantages at the biological and experimental levels, and their respective use for evaluating the effect of antiviral molecules on different steps of HCV biology including virus entry, replication, particles generation and excretion, as well as on the modulation by the virus of the host cell response to infection.

  • Genetic Alliance. consumer health - Hepatitis.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19555718.001).
  • [ISSN] 1879-016X
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / RNA, Viral; 0 / Viral Hepatitis Vaccines
  • [Number-of-references] 337
  •  go-up   go-down


71. Phillips A, Hood SR, Gibson GG, Plant NJ: Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression. Drug Metab Dispos; 2005 Feb;33(2):233-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent data have made it increasingly clear that the gene expression profile of a cell system, and its alteration in response to external stimuli, is highly dependent on both the higher order chromatin structure of the genome and the interaction of gene products in interpreting stimuli.
  • To further explore this phenomenon, we have examined the role of both of these factors in controlling xenobiotic-mediated gene expression changes in primary and transformed human hepatocytes (HuH7).
  • Using quantitative polymerase chain reaction, expression levels of several transcription factors implicated in the liver-specific regulation of the CYP3A gene family were examined in human adult and fetal liver RNA samples.
  • These expression profiles were then compared with those obtained from both primary and transformed human hepatocytes, showing that, in general, cultured cells exhibit a distinct profile compared with either the fetal or adult samples.
  • Whereas exposure to these compounds elicited a dose-dependent increase in CYP3A transcription in primary hepatocytes, no alteration in expression levels was observed for the hepatoma cell line HuH7.
  • Alteration in the expression levels of pregnane X receptor and chicken ovalbumin upstream promoter transcription factor I, and the disruption of higher order chromatin within HuH7 cells altered CYP3A expression and/or activation by xenobiotics toward that observed in primary hepatocytes.
  • [MeSH-minor] Adult. Aged. Cell Line. Cytochrome P-450 CYP3A. Female. Fetus / enzymology. Humans. Male. Middle Aged. Protein Conformation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15523048.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Transcription Factors; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


72. Gao J, Chen M, Peng ML, Ren H: [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi; 2005 Mar;13(3):198-201
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].
  • OBJECTIVE: To investigate T cell-mediated antitumor effects of dendritic cells (DCs) pulsed with tumor lysates in patients with hepatocellular carcinoma (HCC) in vitro.
  • METHODS: DCs isolated from peripheral blood mononuclear cells of HCC patients were cultured and proliferated in vitro by using recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4), and then were pulsed with autologous hepatoma cell lysates.
  • The ability of DCs pulsed with hepatoma cell lysates to stimulate proliferation of autologous T lymphocytes (CTL) was tested by thymidine incorporation method.
  • RESULTS: The hepatoma cell lysates pulsed DC vaccines led to up-regulation of CD1a, CD40, CD86 and HLA-DR.
  • Concentrations of IFN-gamma and IL-12 were increased more in the hepatoma cell lysate pulsed DCs group than those in the unpulsed DCs group, the hepatoma cell lysate group and control group.
  • The proliferation of T-cells was markedly enhanced in the hepatoma cell lysate pulsed DCs group than that in the others.
  • The CTL stimulated by the hepatoma cell lysate pulsed DCs had much higher cytotoxicity to autologous hepatoma cells (killing rate: 81.72%+/-9.49%), as compared with HepG2 and HNE-1 tumor cells (killing rate: 49.37%+/-11.21% and 17.14%+/-5.65%, respectively).
  • CONCLUSION: The hepatoma cell lysate pulsed DC vaccines can induce an effective and specific anti-hepatoma effect.
  • [MeSH-major] Cancer Vaccines / immunology. Dendritic Cells / immunology. Liver Neoplasms / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Adult. Antigens, Neoplasm / immunology. Carcinoma, Hepatocellular / immunology. Extracellular Matrix Proteins / immunology. Female. Humans. Immunotherapy / methods. Male. Middle Aged. Vaccination

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15760555.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Extracellular Matrix Proteins
  •  go-up   go-down


73. Guguen-Guillouzo C, Corlu A, Guillouzo A: Stem cell-derived hepatocytes and their use in toxicology. Toxicology; 2010 Mar 30;270(1):3-9
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell-derived hepatocytes and their use in toxicology.
  • Besides primary hepatocytes and transformed liver cell lines, stem cells either isolated from embryos or adult tissues or obtained by reprogramming somatic cells are emerging as a new potential source of unlimited numbers of hepatocytes.
  • Presently, only hepatocyte-like cells expressing low levels of liver-specific markers, especially drug metabolizing and detoxifying enzymes, are usually obtained, making them still unsuitable as metabolically competent cells for toxicity studies.
  • The only exceptions are some hepatoma cell lines, particularly the HepaRG cell line that can differentiate from a bipotent progenitor stage to attain the functional capacity of normal adult hepatocytes in primary culture without losing the indefinite growth property of transformed cells.
  • [MeSH-minor] Adult. Animals. Cell Line, Tumor. Embryonic Stem Cells / drug effects. Female. Humans. Hybrid Cells. Liver / pathology. Liver Neoplasms / pathology. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19815049.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 60
  •  go-up   go-down


74. Srisawat N, Avihingsanon A, Praditpornsilpa K, Jiamjarasrangsi W, Eiam-Ong S, Avihingsanon Y: A prevalence of posttransplantation cancers compared with cancers in people with human immunodeficiency virus/acquired immunodeficiency syndrome after highly active antiretroviral therapy. Transplant Proc; 2008 Oct;40(8):2677-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risks of developing hepatoma and non-Hodgkin's lymphoma were comparable between the groups.
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / epidemiology. Female. Humans. Liver Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Middle Aged. Prevalence. Retrospective Studies. Survival Analysis. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929833.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


75. Leung JC, Chan LY, Tang SC, Tam PC, Fenn J, Lai KN: Glycosylation profile of differently charged IgA1 and their binding characteristics to cultured mesangial cells in IgA nephropathy. Nephron Exp Nephrol; 2007;107(3):e107-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The binding characteristics of these IgA1 fractions to cultured human mesangial cells (HMC) and hepatoma cell lines (HepG2) were studied.
  • [MeSH-minor] Acetylgalactosamine / analysis. Adult. Anions. Binding, Competitive. Cations. Cell Line, Tumor / metabolism. Cells, Cultured / metabolism. Cells, Cultured / pathology. Female. Galactose / analysis. Glycosylation / drug effects. Humans. Male. Middle Aged. N-Acetylneuraminic Acid / analysis. Neuraminidase / pharmacology. Protein Binding

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17957128.001).
  • [ISSN] 1660-2129
  • [Journal-full-title] Nephron. Experimental nephrology
  • [ISO-abbreviation] Nephron Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anions; 0 / Cations; 0 / Immunoglobulin A; 0 / polymeric IgA; EC 3.2.1.18 / Neuraminidase; GZP2782OP0 / N-Acetylneuraminic Acid; KM15WK8O5T / Acetylgalactosamine; X2RN3Q8DNE / Galactose
  •  go-up   go-down


76. Kaneki M, Hosoi T, Ouchi Y, Orimo H: Pleiotropic actions of vitamin K: protector of bone health and beyond? Nutrition; 2006 Jul-Aug;22(7-8):845-52
Hazardous Substances Data Bank. PHYTONADIONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accumulated evidence indicates that subclinical non-hemostatic vitamin K deficiency in extrahepatic tissues, particularly in bone and possibly in vasculature, exists widely in the otherwise healthy adult population.
  • Most of the new biological functions of vitamin K in bone, vasculature, and hepatoma cells are considered attributable to promotion of gamma-carboxylation of glutamic acid residues in vitamin K-dependent proteins, which is shared by vitamins K1 and K2.
  • [MeSH-minor] Animals. Atherosclerosis / prevention & control. Calcinosis. Carcinoma, Hepatocellular / prevention & control. Humans. Liver Neoplasms / prevention & control. Osteoporosis / drug therapy. Osteoporosis / epidemiology. Osteoporosis / prevention & control. Vitamin K 1 / therapeutic use. Vitamin K 2 / analogs & derivatives. Vitamin K 2 / therapeutic use. Vitamin K Deficiency / complications. Vitamin K Deficiency / physiopathology

  • MedlinePlus Health Information. consumer health - Vitamin K.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815498.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11032-49-8 / Vitamin K 2; 12001-79-5 / Vitamin K; 27Y876D139 / menatetrenone; 84-80-0 / Vitamin K 1
  • [Number-of-references] 78
  •  go-up   go-down


77. Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X: miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer; 2010;10:354
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells.
  • BACKGROUND: In recent years, some miRNAs have been reported to be connected closely with the development of human hepatocellular carcinoma.
  • METHODS: The expression profiles of miR-183 were compared between HCC tissues and adjacent normal liver tissues using qRT-PCR method.
  • Finally, the functional effect of miR-183 in hepatoma cells was examined.
  • RESULTS: Among the 25 HCC samples analyzed, microRNA-183 was significantly up-regulated (twofold to 367-fold) in 17 samples compared with the matching nontumoral liver tissues.
  • Programmed cell death 4 (PDCD4) was identified as the target gene of miR-183.
  • [MeSH-major] Apoptosis. Apoptosis Regulatory Proteins / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. MicroRNAs / physiology. RNA-Binding Proteins / metabolism. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. DNA Primers / chemistry. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Liver / metabolism. Liver / pathology. Luciferases / metabolism. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):26-37 [12482958.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1915-22 [19276261.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6034-41 [16024603.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1573-6 [16081698.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] J Cell Biochem. 2006 Oct 15;99(3):671-8 [16924677.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6101-12 [16682950.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):664-73 [18245465.001]
  • [Cites] Cell Res. 2008 Mar;18(3):350-9 [18270520.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1223-32 [18307259.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):257-69 [18555017.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4820-9 [18427550.001]
  • [Cites] Nucleic Acids Res. 2008 Sep;36(16):5391-404 [18701644.001]
  • [Cites] FEBS Lett. 2008 Oct 29;582(25-26):3663-8 [18840437.001]
  • [Cites] Cytogenet Cell Genet. 1999;87(1-2):113-4 [10640828.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Int J Oncol. 2009 Apr;34(4):1069-75 [19287964.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2170-5 [9605762.001]
  • (PMID = 20602797.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DNA Primers; 0 / MIRN183 microRNA, human; 0 / MicroRNAs; 0 / PDCD4 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins; 0 / Transforming Growth Factor beta1; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2909210
  •  go-up   go-down


78. Yndestad A, Haukeland JW, Dahl TB, Bjøro K, Gladhaug IP, Berge C, Damås JK, Haaland T, Løberg EM, Linnestad P, Birkeland K, Konopski Z, Halvorsen B, Berge RK, Aukrust P: A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol; 2009 Sep;104(9):2196-205
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A complex role of activin A in non-alcoholic fatty liver disease.
  • OBJECTIVES: Recent studies suggest that activin A, a member of the transforming growth factor (TGF) superfamily, is involved in the pathogenesis of liver disorders.
  • We sought to explore its possible role in non-alcoholic fatty liver disease (NAFLD).
  • Gene expression was quantified in liver biopsies obtained from patients with NAFLD (n=13) and controls (n=6).
  • Effects of activin A were examined in Huh7 (human hepatoma cell line) hepatocytes.
  • Liver biopsies from NAFLD patients showed a markedly increased activin A-follistatin mRNA ratio, indicating increased hepatic activin A activity.
  • [MeSH-major] Activins / blood. Fatty Liver / blood. Follistatin / blood. Liver Cirrhosis / blood
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Gene Expression. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Non-alcoholic steatohepatitis (NASH).
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19532130.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Follistatin; 0 / activin A; 104625-48-1 / Activins
  •  go-up   go-down


79. Cifuentes D, Martínez-Pons C, García-Rocha M, Galina A, Ribas de Pouplana L, Guinovart JJ: Hepatic glycogen synthesis in the absence of glucokinase: the case of embryonic liver. J Biol Chem; 2008 Feb 29;283(9):5642-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic glycogen synthesis in the absence of glucokinase: the case of embryonic liver.
  • Glucokinase (GK, hexokinase type IV) is required for the accumulation of glycogen in adult liver and hepatoma cells.
  • Here we address how mammalian embryonic livers, but not adult livers or hepatoma cells, manage to accumulate glycogen in the absence of this enzyme.
  • We engineered FTO2B cells, a hepatoma cell line in which GK is not expressed, to unveil the modifications required to allow them to accumulate glycogen.
  • In the light of these results, we then examined glycogen metabolism in embryonic liver.
  • We conclude that although the GK/liver glycogen synthase tandem is ideally suited to store glycogen in liver when blood glucose is high, the substitution of HKI for GK in embryonic livers allows the HKI/liver glycogen synthase tandem to make glycogen independently of the glucose concentration in blood, although it requires huge levels of HK.
  • Moreover, the physiological consequence of the HK isoform switch is that the embryonic liver safeguards its glycogen deposits, required as the main source of energy at birth, from maternal starvation.
  • [MeSH-major] Embryo, Mammalian / enzymology. Gene Expression Regulation, Developmental. Gene Expression Regulation, Enzymologic. Glucokinase. Glycogen / biosynthesis. Hexokinase / biosynthesis. Liver / enzymology
  • [MeSH-minor] Animals. Blood Glucose / genetics. Blood Glucose / metabolism. Carrier Proteins / genetics. Carrier Proteins / metabolism. Cell Line, Tumor. Female. Glycogen Synthase / genetics. Glycogen Synthase / metabolism. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Isoenzymes / genetics. Isoenzymes / metabolism. Mice. Pregnancy. Rats

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165236.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Carrier Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Isoenzymes; 0 / Ppp1r3c protein, mouse; 0 / Ppp1r5 protein, rat; 9005-79-2 / Glycogen; EC 2.4.1.11 / Glycogen Synthase; EC 2.7.1.1 / HK1 protein, mouse; EC 2.7.1.1 / Hexokinase; EC 2.7.1.2 / Glucokinase
  •  go-up   go-down


80. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Soliman T, Steininger R, Muehlbacher F, Berlakovich GA: Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int; 2006 Apr;19(4):275-81
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Model for end-stage liver disease (MELD) score has emerged as a useful tool in predicting mortality in patients awaiting liver transplantation.
  • From 1997 to 2003, 621 adult patients with end-stage liver disease were listed for orthotopic liver transplantation (OLT).
  • Patients suffering from hepatoma were excluded from analysis (113 patients).
  • [MeSH-major] Liver Failure / mortality. Liver Failure / surgery. Liver Transplantation / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Models, Biological. Resource Allocation. Risk Factors. Survival Rate. Tissue and Organ Procurement. Waiting Lists

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transpl Int. 2006 Apr;19(4):270-4 [16573541.001]
  • (PMID = 16573542.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Cowherd RB, Asmar MM, Alderman JM, Alderman EA, Garland AL, Busby WH, Bodnar WM, Rusyn I, Medoff BD, Tisch R, Mayer-Davis E, Swenberg JA, Zeisel SH, Combs TP: Adiponectin lowers glucose production by increasing SOGA. Am J Pathol; 2010 Oct;177(4):1936-45
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adiponectin is a hormone that lowers glucose production by increasing liver insulin sensitivity.
  • Mass spectrometry revealed a novel protein that we call suppressor of glucose by autophagy (SOGA) in adiponectin-treated hepatoma cells.
  • Furthermore, knockdown of SOGA increased late autophagosome and lysosome staining and the secretion of valine, an amino acid that cannot be synthesized or metabolized by liver cells, suggesting that SOGA inhibits autophagy.

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2007 Nov;14(11):1948-57 [17690712.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6763-72 [17192262.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):7991-6 [17244624.001]
  • [Cites] Autophagy. 2008 Feb;4(2):151-75 [18188003.001]
  • [Cites] Autophagy. 2007 May-Jun;3(3):238-40 [17224623.001]
  • [Cites] Nat Protoc. 2007;2(4):953-71 [17446895.001]
  • [Cites] Am J Clin Nutr. 2007 May;85(5):1275-85 [17490963.001]
  • [Cites] Annu Rev Nutr. 2007;27:329-45 [17465853.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):35069-77 [17905742.001]
  • [Cites] Mol Biol Cell. 2008 May;19(5):2092-100 [18321988.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1131-5 [19339967.001]
  • [Cites] Trends Pharmacol Sci. 2009 May;30(5):234-9 [19359049.001]
  • [Cites] Cell Death Differ. 2009 Jul;16(7):956-65 [19373247.001]
  • [Cites] Biochem Soc Trans. 2009 Aug;37(Pt 4):751-5 [19614588.001]
  • [Cites] Exp Mol Med. 2009 Aug 31;41(8):577-83 [19381067.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9 [10845877.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1930-5 [11344187.001]
  • [Cites] Nat Med. 2001 Aug;7(8):947-53 [11479628.001]
  • [Cites] Diabetes. 2001 Sep;50(9):2094-9 [11522676.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1875-81 [11748271.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1288-95 [12368907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16309-13 [12456889.001]
  • [Cites] Diabetes. 2003 Feb;52(2):268-76 [12540596.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16820-7 [12621049.001]
  • [Cites] Nature. 2003 Jun 12;423(6941):762-9 [12802337.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1431-2 [14602433.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14217-22 [14617771.001]
  • [Cites] Endocrinology. 2004 Jan;145(1):367-83 [14576179.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):8452-9 [14610086.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):15719-22 [14970221.001]
  • [Cites] Diabetes Care. 2004 Jun;27(6):1365-8 [15161789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10308-13 [15210937.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9 [15356026.001]
  • [Cites] J Clin Invest. 1974 Jul;54(1):188-93 [4834889.001]
  • [Cites] Nature. 1979 Sep 13;281(5727):117-21 [471058.001]
  • [Cites] Cell Tissue Res. 1986;243(3):641-8 [3955637.001]
  • [Cites] Annu Rev Nutr. 1987;7:539-64 [3300746.001]
  • [Cites] Am J Physiol. 1992 Nov;263(5 Pt 1):E856-62 [1443117.001]
  • [Cites] J Biol Chem. 1995 Feb 3;270(5):2320-6 [7836465.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1353-61 [9525977.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4891-8 [10490823.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1637-44 [16424193.001]
  • [Cites] J Biol Chem. 2006 Feb 3;281(5):2654-60 [16326714.001]
  • [Cites] Endocrinology. 2006 May;147(5):2432-41 [16455782.001]
  • [Cites] Nat Cell Biol. 2006 May;8(5):516-23 [16622416.001]
  • [Cites] Pathol Res Pract. 2006;202(9):631-8 [16781826.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):34870-9 [16990266.001]
  • [Cites] Mol Cell. 2007 Jan 26;25(2):193-205 [17244528.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):218-24 [17237771.001]
  • [CommentIn] Am J Pathol. 2010 Oct;177(4):1600-2 [20813966.001]
  • [ErratumIn] Am J Pathol. 2011 Mar;178(3):1406. Cowerd, Rachael B [corrected to Cowherd, Rachael B]
  • (PMID = 20813965.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ FJ977045
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NIAID NIH HHS / AI / AI066075; United States / NIDDK NIH HHS / DK / K01 DK075573; United States / NIDDK NIH HHS / DK / DK075573; United States / NIAID NIH HHS / AI / R01 AI066075; United States / NIEHS NIH HHS / ES / ES010126; United States / NIDDK NIH HHS / DK / P30 DK056350; United States / NIDDK NIH HHS / DK / DK056350; United States / NIEHS NIH HHS / ES / P42 ES005948
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Blood Glucose; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Intracellular Signaling Peptides and Proteins; 0 / Peptide Fragments; 0 / SOGA protein, human; 0 / suppressor of glucose by autophagy protein, mouse; EC 2.7.11.1 / AMP-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2947288
  •  go-up   go-down


82. Wong LL, Limm W, Cheung A, Noguchi H: Liver transplant in Hawaii: the survival of a small centre. Clin Transplant; 2006 Jan-Feb;20(1):55-61
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant in Hawaii: the survival of a small centre.
  • Although many report the importance of case volume in complex cases, liver transplantation (LT) can be carried out successfully in a small centre.
  • Indications for LT were primarily hepatitis C (n = 49) and hepatitis B (n = 13) and 22 patients (25%) had hepatocellular cancer (HCC) on explanted liver.
  • There was no primary graft nonfunction, one retransplant for recurrent hepatitis C and two late hepatic artery thromboses, which did not require a retransplant.
  • During this time period, 142 liver resections, 77 pancreatic resections and 43 splenorenal shunts were performed by this group of surgeons.
  • [MeSH-major] Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Female. Hawaii. Hepatitis B / surgery. Hepatitis C / surgery. Humans. Male. Middle Aged. Quality of Health Care. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556154.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


83. Naiki T, Nagaki M, Asano T, Kimata T, Moriwaki H: Adenovirus-mediated hepatocyte nuclear factor-4alpha overexpression maintains liver phenotype in cultured rat hepatocytes. Biochem Biophys Res Commun; 2005 Sep 23;335(2):496-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenovirus-mediated hepatocyte nuclear factor-4alpha overexpression maintains liver phenotype in cultured rat hepatocytes.
  • Hepatocyte nuclear factor 4alpha (HNF-4alpha) is a transcription factor that controls embryonal liver development and that maintains and regulates gene expression in adult liver cells.
  • We have previously demonstrated that transient overexpression of HNF-4alpha up-regulates a number of liver-specific genes in hepatoma cell lines.
  • In this study, we extend these studies by assessing the functional role of HNF-4alpha in regulating cellular viability and liver-specific functions of primary rat hepatocytes.
  • In cells transfected with an adenovirus vector carrying rat HNF-4alpha cDNA, induction and maintenance of liver-specific genes and functions were observed over a long-term culture, which might be associated with the prevention of a rapid loss of the mitochondrial membrane potential.
  • In addition, we demonstrated that transthyretin mRNA was up-regulated by HNF-4alpha in primary hepatocytes, but not in hepatoma cells.
  • These results indicate that HNF-4alpha plays a role in the maintenance of morphologically and biochemically functional hepatocytes and that the difference in expression of liver-specific genes induced by HNF-4alpha may depend on a differentiation state of cells.
  • [MeSH-major] Adenoviridae / genetics. DNA-Binding Proteins / metabolism. Gene Expression Regulation. Liver / pathology. Phosphoproteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Ammonia / chemistry. Ammonia / pharmacology. Animals. Blotting, Northern. Cell Differentiation. Cell Survival. DNA, Complementary / metabolism. Genetic Vectors. Gentian Violet / pharmacology. Hepatocyte Nuclear Factor 4. Hepatocytes / cytology. Hepatocytes / metabolism. Intracellular Membranes / metabolism. Male. Membrane Potentials. Microscopy, Phase-Contrast. Mitochondria / metabolism. Phenotype. Rats. Rats, Wistar. Time Factors. Transcription, Genetic. Up-Regulation. beta-Galactosidase / metabolism

  • Hazardous Substances Data Bank. Gentian Violet .
  • Hazardous Substances Data Bank. Ammonia .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16087161.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / Hepatocyte Nuclear Factor 4; 0 / Phosphoproteins; 0 / Transcription Factors; 7664-41-7 / Ammonia; EC 3.2.1.23 / beta-Galactosidase; J4Z741D6O5 / Gentian Violet
  •  go-up   go-down


84. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L: Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer; 2009 Oct 1;125(7):1640-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients.
  • This study investigated the properties of FoxP3(+) Tregs, their prognostic value in patients with hepatocellular carcinoma (HCC) and the underlying mechanisms of FoxP3(+) Treg intratumoral accumulation.
  • In addition to an increased number of circulating FoxP3(+) Tregs, the results also showed that FoxP3(+) Tregs gathered in the tumor site, where they suppressed tissue-derived CD4(+)CD25(-) T-cell activation (p < 0.001), promoting disease progression and poor prognosis in HCC patients (< 0.01).
  • Depletion of tissue Mvarphi thus attenuated the increase of liver FoxP3(+) Treg frequency attributed to in vivo inoculation with hepatoma (p = 0.01), whereas Mvarphi exposed to tumor culture supernatants from hepatoma-derived cell lines increased FoxP3(+) Treg frequency in vitro (p < 0.001).
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Forkhead Transcription Factors / metabolism. Liver Neoplasms / immunology. Macrophages / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Disease Progression. Female. Flow Cytometry. Humans. Immunohistochemistry. Male. Microscopy, Confocal. Middle Aged. Odds Ratio. Phenotype. Predictive Value of Tests. Prognosis. Proportional Hazards Models

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19569243.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


85. Selvasekaran R, Cherian JV, Venkataraman J: Metastasis of hepatocellular carcinoma to Virchow's node: have the tumor cells gone astray? Hepatobiliary Pancreat Dis Int; 2007 Dec;6(6):650-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of hepatocellular carcinoma to Virchow's node: have the tumor cells gone astray?
  • It is rarely involved in hepatocellular carcinoma.
  • METHOD: We report on a patient with hepatoma who had metastasis to the left supraclavicular node at presentation.
  • He was hepatitis B surface antigen positive, had elevated serum alpha-fetoprotein levels, and transabdominal imaging showed a space-occupying lesion in the right lobe of the liver.
  • Fine needle aspiration of the left supraclavicular node revealed a poorly differentiated carcinoma.
  • CONCLUSION: Metastasis to the Virchow-Trosier node in hepatoma, although uncommon, can occur probably via the hepatic node and then through the thoracic duct.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adult. Clavicle. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086635.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A: Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol; 2009 Nov;35(5):1005-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
  • Des-gamma-carboxy prothrombin (DCP) is a well-established tumor marker for hepatocellular carcinoma (HCC), but the precise mechanism by which HCC cells produce DCP remains unknown.
  • Hepatoma cell lines (HepG2 and PLC/PRF/5) were induced EFC or epithelial-mesenchymal transition (EMT) by phorbol 12-myristate 13 acetate (TPA) or transforming growth factor (TGF)-beta1.
  • Labeled low-density lipoprotein (LDL) uptake (as a surrogate for vitamin K) was significantly impaired in DCP-producing hepatoma cells following induction of EFC or EMT.
  • Latrunculin A, an actin depolymerizer, induced naïve hepatoma cells to produce DCP with impairment of labeled-LDL uptake.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cytoskeleton / pathology. Liver Neoplasms / metabolism. Protein Precursors / biosynthesis. Prothrombin / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers. Biomarkers, Tumor / analysis. Blotting, Western. Cadherins / biosynthesis. Cell Line, Tumor. Cholesterol, LDL / metabolism. Enzyme-Linked Immunosorbent Assay. Epithelial Cells / pathology. Female. Flow Cytometry. Humans. Immunohistochemistry. Male. Mesoderm / pathology. Microscopy, Fluorescence. Middle Aged. Vitamin K / metabolism

  • Genetic Alliance. consumer health - Prothrombin.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787254.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cholesterol, LDL; 0 / Protein Precursors; 12001-79-5 / Vitamin K; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


87. Ansermet F, Lespinasse J, Gimelli S, Béna F, Paoloni-Giacobino A: Mild intellectual disability associated with a progeny of father-daughter incest: genetic and environmental considerations. J Child Sex Abus; 2010 May;19(3):337-44
MedlinePlus Health Information. consumer health - Child Sexual Abuse.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Craniofacial Abnormalities / genetics. Craniofacial Abnormalities / psychology. Domestic Violence / psychology. Female. Heterozygote Detection. Humans. Pedigree. Phenotype. Pregnancy. Self Concept

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20509080.001).
  • [ISSN] 1547-0679
  • [Journal-full-title] Journal of child sexual abuse
  • [ISO-abbreviation] J Child Sex Abus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / hepatoma-derived growth factor
  •  go-up   go-down


88. Tanaka Y, Kanai F, Tada M, Tateishi R, Sanada M, Nannya Y, Ohta M, Asaoka Y, Seto M, Shiina S, Yoshida H, Kawabe T, Yokosuka O, Ogawa S, Omata M: Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. J Hepatol; 2008 Nov;49(5):746-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma.
  • BACKGROUND/AIMS: The aim of this study is to identify genomic changes that might be implicated in hepatocellular carcinoma (HCC) progression, and evaluate the associations with clinico-pathological features.
  • METHODS: The genomic DNA of 17 hepatoma cell lines was analyzed using Affymetrix GeneChip Human Mapping 50K high-density oligonucleotide arrays.
  • RESULTS: We found 10 recurrent high-grade gain regions spanning less than 3 Mb in at least two hepatoma cell lines, and selected 10 representative genes.
  • Decreased GRHL2 expression by RNA interference inhibits the growth of hepatoma cells, suggesting its association with cell proliferation.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA-Binding Proteins / genetics. Gene Dosage. Liver Neoplasms / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Base Sequence. Biomarkers, Tumor / genetics. Cell Line, Tumor. Child. DNA Primers / genetics. Disease-Free Survival. Female. Humans. Infant. Intracellular Signaling Peptides and Proteins / genetics. Loss of Heterozygosity. Male. Middle Aged. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. RNA Interference. Recurrence. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752864.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / GRHL2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / TAX1BP1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


89. Li X, Feng P, Ou J, Luo Z, Dai P, Wei D, Zhang C: Dermatopontin is expressed in human liver and is downregulated in hepatocellular carcinoma. Biochemistry (Mosc); 2009 Sep;74(9):979-85
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatopontin is expressed in human liver and is downregulated in hepatocellular carcinoma.
  • Dermatopontin (DPT) was recently found as a downstream target of vitamin D receptor, which is a key molecule in the 1,25-dihydroxy-vitamin D(3) anti-hepatoma proliferation pathway.
  • The aim of this study was to analyze DPT expression in hepatocellular carcinoma (HCC) based on the analysis for DPT gene in normal tissues in order to estimate its function in the progression of HCC.
  • DPT mRNA expression was analyzed in normal tissues and HCC cell lines by RT-PCR, and in HCC tissue by RT-PCR and real-time PCR.
  • The results showed that DPT mRNA was strongly expressed in human fetal and adult liver, kidney, and spleen, weakly in ovary and heart, and absent in other tissues and HCC cell lines examined.
  • DPT is located mainly in the cytoplasm of several cell types in the liver; it has been identified also in the extracellular matrix of the skin.
  • [MeSH-major] Chondroitin Sulfate Proteoglycans / metabolism. Down-Regulation. Extracellular Matrix Proteins / metabolism. Liver / metabolism. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Base Sequence. Blotting, Western. DNA Primers. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Transforming Growth Factor beta1 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19916908.001).
  • [ISSN] 1608-3040
  • [Journal-full-title] Biochemistry. Biokhimii︠a︡
  • [ISO-abbreviation] Biochemistry Mosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chondroitin Sulfate Proteoglycans; 0 / DNA Primers; 0 / DPT protein, human; 0 / Extracellular Matrix Proteins; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


90. Su N, Thiaville MM, Awad K, Gjymishka A, Brant JO, Yang TP, Kilberg MS: Protein or amino acid deprivation differentially regulates the hepatic forkhead box protein A (FOXA) genes through an activating transcription factor-4-independent pathway. Hepatology; 2009 Jul;50(1):282-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FOXA (forkhead box A) proteins (FOXA1, FOXA2, and FOXA3) play a critical role in the development of the liver, and they also regulate metabolism in adult hepatic tissue.
  • The liver responds to changes in nutrient availability by initiating a number of stress signaling pathways.
  • Conversely, fetal liver did not exhibit this regulation.
  • Amino acid deprivation of HepG2 hepatoma cells also enhanced transcription from the FOXA2 and FOXA3 genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Cell Mol Life Sci. 2006 Oct;63(19-20):2317-28 [16909212.001]
  • [Cites] Mol Cell. 2000 May;5(5):897-904 [10882126.001]
  • [Cites] J Endocrinol. 2000 Oct;167(1):R1-5 [11018767.001]
  • [Cites] Trends Endocrinol Metab. 2000 Sep;11(7):281-5 [10920385.001]
  • [Cites] J Biol Chem. 2004 Jan 30;279(5):3463-71 [14623874.001]
  • [Cites] Biochem J. 2004 Apr 1;379(Pt 1):79-88 [14715082.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11269-74 [15277680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12986-91 [15317935.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):27-33 [15479734.001]
  • [Cites] Development. 1993 May;118(1):47-59 [8375339.001]
  • [Cites] Development. 1993 Nov;119(3):567-78 [8187630.001]
  • [Cites] Cell. 1994 Aug 26;78(4):561-74 [8069909.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):341-9 [8825036.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3995-4006 [9233809.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4245-51 [9632808.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10152-7 [10468578.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50829-39 [15385533.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13809-16 [15668254.001]
  • [Cites] FEBS Lett. 2005 May 9;579(12):2609-14 [15862298.001]
  • [Cites] Annu Rev Nutr. 2005;25:59-85 [16011459.001]
  • [Cites] Annu Rev Microbiol. 2005;59:407-50 [16153175.001]
  • [Cites] Biol Chem. 2005 Sep;386(9):873-9 [16164412.001]
  • [Cites] Biochem J. 2005 Nov 1;391(Pt 3):649-58 [16026328.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1111-24 [16777601.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):17929-40 [16621798.001]
  • [Cites] Biochem J. 2008 Mar 15;410(3):473-84 [18052938.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):7064-73 [18195013.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27736-47 [18697751.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5175-83 [10866673.001]
  • (PMID = 19415718.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK052064; United States / NIDDK NIH HHS / DK / R01 DK070647; United States / NIDDK NIH HHS / DK / DK-52064; United States / NIDDK NIH HHS / DK / DK70647
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Foxa1 protein, mouse; 0 / Foxa2 protein, mouse; 0 / Foxa3 protein, mouse; 0 / Hepatocyte Nuclear Factor 3-alpha; 0 / Proteins; 135845-91-9 / Hepatocyte Nuclear Factor 3-gamma; 135845-92-0 / Hepatocyte Nuclear Factor 3-beta; 145891-90-3 / Activating Transcription Factor 4
  • [Other-IDs] NLM/ NIHMS447414; NLM/ PMC3594789
  •  go-up   go-down


91. Bozzo C, Tiberio R, Graziola F, Pertusi G, Valente G, Colombo E, Small PL, Leigheb G: A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells. Microbes Infect; 2010 Dec;12(14-15):1258-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells.
  • In contrast, mycolactone A/B was devoid of toxicity neither on human hepatoma HuH7 nor on human embryonic kidney HEK 293 T cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Institut Pasteur. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20800104.001).
  • [ISSN] 1769-714X
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Lactones; 0 / Macrolides; 0 / mycolactone A; 0 / mycolactone B
  •  go-up   go-down


92. Cho YG, Kim CJ, Song JH, Rhie DJ, Park YK, Kim SY, Nam SW, Yoo NJ, Lee JY, Park WS: Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas. Exp Mol Med; 2006 Jun 30;38(3):247-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas.
  • This study analyzed the mutation, allelic loss and expression patterns of the KCNRG gene in 77 HCCs in order to determine if the KCNRG gene, which encodes the potassium channel regulating protein, is involved in the tumorigenesis of hepatocellular carcinoma (HCC).
  • Hep3B hepatoma cells were transfected with the wild- or mutant-KCNRG to determine the effect of this mutation in KCNRG.
  • Interestingly, the suppressive cell growth activity of the mutant-type KCNRG was significantly lower than that of the wild-type KCNRG.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Potassium Channels / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Proliferation. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Loss of Heterozygosity / genetics. Male. Membrane Potentials / genetics. Membrane Potentials / physiology. Middle Aged. Mutation / genetics. Polymorphism, Single-Stranded Conformational. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819283.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / KCNRG protein, human; 0 / Potassium Channels
  •  go-up   go-down


93. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol; 2005 Dec;43(6):1013-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
  • BACKGROUND/AIMS: MHC class I-related chain A (MICA), a human ligand of natural killer (NK) cell stimulatory receptor NKG2D, is expressed in human hepatocellular carcinomas (HCC).
  • In vitro experiments were performed to examine the impact of sMICA on NK cell expression of NKG2D and subsequent dendritic cell (DC) activation.
  • In vitro experiments revealed that sMICA derived from advanced HCC was responsible for down-modulation of NKG2D expression and NK cell functions.
  • NK cells upon stimulation of human hepatoma cells induced maturation of DC and enhanced the allostimulatory capacity of DC; maturation and activation of DC were completely abolished when NK cells were pre-treated with sMICA-containing serum.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Dendritic Cells / immunology. Histocompatibility Antigens Class I / immunology. Killer Cells, Natural / immunology. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis, Chronic / immunology. Humans. Male. Middle Aged. NK Cell Lectin-Like Receptor Subfamily K. Receptors, Immunologic / immunology. Receptors, Natural Killer Cell

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168521.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KLRK1 protein, human; 0 / MHC class I-related chain A; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Immunologic; 0 / Receptors, Natural Killer Cell
  •  go-up   go-down


94. Huang X, Yu C, Jin C, Kobayashi M, Bowles CA, Wang F, McKeehan WL: Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res; 2006 Feb 1;66(3):1481-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroblast growth factor (FGF) signaling mediates cell-to-cell communication in development and organ homeostasis in adults.
  • Although FGFR1 is expressed by hepatic cell progenitors and adult nonparenchymal cells, ectopic expression is commonly observed in hepatoma cells.
  • Here, we determined whether ectopic FGFR1 is a cause or consequence of hepatocellular carcinoma by targeting a constitutively active human FGFR1 to mouse hepatocytes.
  • However, in diethylnitrosamine-treated mice, the chronic FGFR1 activity promoted an incidence of 44% adenomas at 4 months and 38% hepatocellular carcinoma at 8 months.
  • No adenoma or hepatocellular carcinoma was observed in diethylnitrosamine-treated wild-type (WT) livers at 4 or 8 months, respectively.
  • Isolated hepatoma cells from the transgenic tumors exhibited a growth advantage in culture.
  • Advanced hepatocellular carcinoma in the transgenic livers exhibited a reduced rate of necrosis.
  • In cooperation with an initiator, the persistent activity of ectopic FGFR1 in hepatocytes is a strong promoter of hepatocellular carcinoma by driving cell proliferation at early stages and promoting neoangiogenesis at late stages of progression.
  • [MeSH-major] Hepatocytes / metabolism. Liver Neoplasms, Experimental / metabolism. Receptor, Fibroblast Growth Factor, Type 1 / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Animals. Carcinogens. Cell Growth Processes / physiology. Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. DNA, Neoplasm / biosynthesis. Diethylnitrosamine. Hepatectomy. Humans. Liver / drug effects. Liver / physiology. Liver Regeneration / physiology. MAP Kinase Signaling System. Mice. Mice, Transgenic. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452204.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 59971; United States / NIDDK NIH HHS / DK / R01 DK 35310; United States / NCI NIH HHS / CA / U01 CA 84296
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA, Neoplasm; 0 / Vascular Endothelial Growth Factor A; 3IQ78TTX1A / Diethylnitrosamine; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  •  go-up   go-down


95. Bylesjö I, Wikberg A, Andersson C: Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest; 2009;69(5):612-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatoma was strikingly overrepresented.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Clinical Laboratory Techniques. Female. Heterozygote. Humans. Insurance, Disability. Male. Middle Aged. Sick Leave. Smoking. Sweden. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Acute Intermittent Porphyria.
  • Genetic Alliance. consumer health - Porphyria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401933.001).
  • [ISSN] 1502-7686
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Abdel-Wahab M, Mostafa M, Sabry M, el-Farrash M, Yousef T: Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1754-9
Hazardous Substances Data Bank. AFLATOXIN B1 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study.
  • The co-contamination of foodstuffs with this mycotoxin is well known and has been possibly implicated in the development of hepatocellular carcinoma in high risk regions around the world.
  • This study investigates the serum aflatoxin B1 in patients with hepatocellular carcinoma and compares it to a control group.
  • METHODOLOGY: From January 2005 to January 2006, 80 cases with hepatocellular carcinoma diagnosed in the Gastroenterology center, Mansoura University, Egypt and 20 healthy subjects used as a control group were enrolled in the study.
  • All patients were evaluated for age, sex, residence, occupation, history of other medical diseases, anti-bilharzial treatment, blood transfusion, viral markers, liver functions and serum level of aflatoxin B1.
  • The serum level of AFB1 was statistically high in Child class B patients compared with class A (P<0.05), high in patients with tumor size > 5 cm compared with tumor size < 5 cm (P<0.05), high in right lobe tumor patients compared with left lobe tumor (P>0.05), high in multifocal hepatoma patients compared with single lesion patients (P<0.05).
  • CONCLUSIONS: Aflatoxin B1 may play an important role in the occurrence of HCC in the north Nile delta area and especially in males, farmers, and rural residents, HCV infection, cirrhotic liver and multifocal hepatoma patients.
  • [MeSH-major] Aflatoxin B1 / toxicity. Carcinoma, Hepatocellular / chemically induced. Liver Neoplasms / chemically induced
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. Female. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102385.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 9N2N2Y55MH / Aflatoxin B1; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


97. Ikeda R, Nishida T, Watanabe F, Shimizu-Saito K, Asahina K, Horikawa S, Teraoka H: Involvement of CCAAT/enhancer binding protein-beta (C/EBPbeta) in epigenetic regulation of mouse methionine adenosyltransferase 1A gene expression. Int J Biochem Cell Biol; 2008;40(9):1956-69
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In mammals, two different genes, MAT1A and MAT2A, encode catalytic polypeptides of liver-specific MAT I/III and ubiquitous MAT II, respectively.
  • Reverse transcription-polymerase chain reaction showed that MAT1A gene expression was at a detectable level in embryonic day 14 mouse fetal liver and subsequently increased.
  • Bisulfite genomic sequencing indicated that the methylation status of 10CpG sites in the MAT1A promoter proximal region was appreciably correlated with the gene expression in mouse developing liver and in adult hepatic cells; hepatic stellate cells and hepatocytes.
  • When mouse hepatoma-derived Hepa-1 cells showing extremely low expression of MAT1A gene were treated with 5-aza-2'-deoxycytidine and trichostatin A, MAT1A gene expression was enhanced.
  • [MeSH-minor] Animals. Binding Sites. Cattle. DNA Methylation. Down-Regulation. Liver / growth & development. Liver / metabolism. Mice. Promoter Regions, Genetic

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346930.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-beta; EC 2.5.1.6 / Mat1a protein, mouse; EC 2.5.1.6 / Methionine Adenosyltransferase
  •  go-up   go-down


98. Vay D, Rigamonti C, Vidali M, Mottaran E, Alchera E, Occhino G, Sartori M, Albano E: Anti-phospholipid antibodies associated with alcoholic liver disease target oxidized phosphatidylserine on apoptotic cell plasma membranes. J Hepatol; 2006 Jan;44(1):183-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-phospholipid antibodies associated with alcoholic liver disease target oxidized phosphatidylserine on apoptotic cell plasma membranes.
  • BACKGROUND/AIMS: Circulating anti-phospholipid antibodies (aPL) are often present in patients with alcoholic liver disease (ALD).
  • METHODS: Apoptosis was induced in HuT-78 human T-lymphoma and HepG2 hepatoma cells by, respectively, FAS ligation with CH11 monoclonal antibodies or the incubation with ethanol (400 mmol/L).
  • [MeSH-major] Antibodies, Antiphospholipid / immunology. Apoptosis / physiology. Cell Membrane / metabolism. Liver Diseases, Alcoholic / metabolism. Oxidative Stress / physiology. Phosphatidylserines / metabolism
  • [MeSH-minor] Adult. Aged. Cells, Cultured. Female. Flow Cytometry. Hepatocytes / metabolism. Hepatocytes / ultrastructure. Humans. Lipid Peroxidation / physiology. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143424.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Phosphatidylserines
  •  go-up   go-down


99. Song BL, Wang CH, Yao XM, Yang L, Zhang WJ, Wang ZZ, Zhao XN, Yang JB, Qi W, Yang XY, Inoue K, Lin ZX, Zhang HZ, Kodama T, Chang CC, Liu YK, Chang TY, Li BL: Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma. Biochem J; 2006 Mar 15;394(Pt 3):617-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma.
  • In normal adult human liver, CDX2 expression is not detectable and the ACAT2 expression is very low.
  • In the hepatoma cell line HepG2 the CDX2 expression is elevated, accounting for its elevated ACAT2 expression.
  • A high percentage (seven of fourteen) of liver samples from patients affected with hepatocellular carcinoma exhibited elevated ACAT2 expression.
  • Thus, the elevated ACAT2 expression may serve as a new biomarker for certain form(s) of hepatocellular carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Jan;156(1):227-36 [10623671.001]
  • [Cites] J Lipid Res. 2005 Sep;46(9):1868-76 [15961790.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):28083-92 [10846185.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):961-71 [11040183.001]
  • [Cites] Nat Med. 2000 Dec;6(12):1341-7 [11100118.001]
  • [Cites] Curr Opin Lipidol. 2001 Jun;12(3):289-96 [11353332.001]
  • [Cites] Circulation. 2001 May 29;103(21):2604-9 [11382731.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):20989-98 [11399774.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):580-8 [11401500.001]
  • [Cites] J Mol Endocrinol. 2001 Aug;27(1):11-29 [11463573.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):32122-8 [11395488.001]
  • [Cites] Nat Cell Biol. 2001 Oct;3(10):905-12 [11584272.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21361-70 [11934881.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):42386-93 [12200448.001]
  • [Cites] Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Jan;35(1):6-12 [12518221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1262-7 [12538880.001]
  • [Cites] Lab Invest. 2003 Nov;83(11):1569-81 [14615411.001]
  • [Cites] Mol Cell Proteomics. 2004 Jan;3(1):73-81 [14593079.001]
  • [Cites] J Lipid Res. 2004 Apr;45(4):686-96 [14729857.001]
  • [Cites] Mol Pharmacol. 2004 Apr;65(4):953-63 [15044625.001]
  • [Cites] Circulation. 2004 Oct 5;110(14):2017-23 [15451793.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):227-38 [15473963.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1088-97 [15486928.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12 [15508073.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S113-9 [15508074.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1225-36 [2364427.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(24):9838-42 [2263635.001]
  • [Cites] Arterioscler Thromb. 1991 Nov-Dec;11(6):1830-43 [1931885.001]
  • [Cites] Am J Physiol. 1993 Sep;265(3 Pt 1):G506-13 [7692743.001]
  • [Cites] J Lipid Res. 1998 Aug;39(8):1722-7 [9717734.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26755-64 [9756919.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1568-74 [9763528.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):6011-9 [10026228.001]
  • [Cites] Biochem J. 2000 Mar 1;346 Pt 2:529-35 [10677375.001]
  • (PMID = 16274362.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL060306; United States / NHLBI NIH HHS / HL / HL60306
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / Homeodomain Proteins; 0 / RNA, Messenger; EC 2.3.1.26 / Sterol O-Acyltransferase; EC 2.3.1.26 / sterol O-acyltransferase 2
  • [Other-IDs] NLM/ PMC1383711
  •  go-up   go-down


100. Shimizu YI, Morita M, Ohmi A, Aoyagi S, Ebihara H, Tonaki D, Horino Y, Iijima M, Hirose H, Takahashi S, Takahashi Y: Fasting induced up-regulation of activating transcription factor 5 in mouse liver. Life Sci; 2009 Jun 19;84(25-26):894-902
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fasting induced up-regulation of activating transcription factor 5 in mouse liver.
  • Atf5 (activating transcription factor 5) is a transcription factor of the ATF/cAMP response element-binding protein family and is expressed abundantly in human liver.
  • Atf5 has been associated with stress responses, cell differentiation, proliferation, and survival.
  • However, its role in the liver response to in vivo food deprivation has not yet been investigated.
  • MAIN METHODS: Adult mice were food-deprived for 48 h and the expression of two Atf5 mRNA subtypes (Atf5-R1 and Atf-R2) and gluconeogenic factors was investigated.
  • Using in vitro cell culture, Pgc-1alpha (peroxisome proliferator-activated receptor-gamma coactivator-1alpha) promoter activities after ectopic expression of Atf5 and Cebpg (CCAAT/enhancer-binding protein gamma) proteins were measured.
  • KEY FINDINGS: The Atf5-R1 transcript was found to be abundant in liver and other energy metabolism-related organs; Atf5-R2 was prominent in the testis.
  • Fasting resulted in elevation of the expression of both Atf5-R1 and R2 in the liver.
  • In human hepatoma cells (HepG2), but not in human cervical carcinoma cells (HeLa), forced expression of Atf5 and Cebpg cooperatively stimulated Pgc-1alpha promoter activity, suggesting that hepatic Pgc-1alpha could be induced by Atf5 and Cebpg in cooperation with other hepatic factors.
  • [MeSH-major] Activating Transcription Factors / genetics. Embryo, Mammalian / metabolism. Fasting. Liver / metabolism
  • [MeSH-minor] Animals. Base Sequence. CCAAT-Enhancer-Binding Proteins / genetics. CCAAT-Enhancer-Binding Proteins / metabolism. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Inbred C57BL. Pregnancy. Promoter Regions, Genetic. RNA, Messenger / analysis. RNA, Messenger / genetics. Transcription Factors / genetics. Transcription Factors / metabolism. Transfection. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19376136.001).
  • [ISSN] 1879-0631
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Activating Transcription Factors; 0 / Atf5 protein, mouse; 0 / CCAAT-Enhancer-Binding Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / peroxisome-proliferator-activated receptor-gamma coactivator-1; 136958-00-4 / Cebpg protein, mouse
  •  go-up   go-down






Advertisement